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Introduction 
The first clear clinical description of cystic fibrosis only appeared in the 1930s. The discovery of a sweat 
electrolyte abnormality and the establishment of autosomal recessive mode of inheritance finally facilitated 
accurate clinical definition of the condition in the 1950s. Cellular and molecular biology successively identified the 
main defect as being one of chloride transport and this was rapidly followed by identification of the cystic fibrosis 
gene on chromosome 7. Subsequent accurate delineation of the basic mechanisms of the disease have generated 
great optimism for future definitive treatment. The ultimate goal is to achieve a permanent genetic correction. 
Indeed, very early gene therapy trials have commenced. However, these are not without problems which will be 
discussed during the meeting. 
In many respects, the clinical therapeutic approaches to cystic -fibrosis have changed little in outline over the 
last three decades. Clearly, there have been advances in antibiotic therapy and in new approaches to chest 
physiotherapy. The only new modalities of therapy to appear have been recombinant DNase and the advent of 
lung transplantation. These will also be discussed in depth during the meeting. 
Much of the difficulty in changing therapeutic approaches has arisen because the basic defects of the condition 
cannot be related to the susceptibility to infection in the respiratory tract. Until this is fully elaborated, it is 
unlikely that there will be much change in the basic management strategy. However, new insights into the 
mechanisms that lead to the development of inflammation in the lung of patients with cystic fibrosis might 
facilitate some novel approaches. Furthermore, gaining insights into the mechanisms of inflammation in the 
airways of patients with cystic fibrosis has implications for all forms of airway inflammation. 
This is an exciting new area of research which will almost certainly have practical implications in the short term 
while awaiting the inevitable development of gene therapy in the longer term. The meeting should provide 
enjoyment and stimulation to all those interested in the clinical and scientific aspects of cystic fibrosis. 
We are grateful for the generous support of Allen & Hanburys Ltd., Bayer plc, Cambridge Books, Eli Lilly & 
Co. Ltd., Merck Sharp & Dohme Ltd., Pharmax Ltd., R&D Systems Ltd., Roche Products Ltd., Southern Self 
Drive Hire, Solvay Healthcare Ltd., UCB Pharma Ltd., Wisdom and Zeneca Pharmaceuticals who sponsored 
this meeting. 
J. 0. WARNER, PROFESSOR OF CHILD HEALTH 
J. K. SHUTE, LECTURER IN IMMUNOPHARMACOLOGY 
Southampton General Hospital, U.K. 
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Invited Speakers 
The primary defect in airway epithelial cells in cystic fibrosis 
R. C. BOUCHER 
CFIPulmonavy Research & Treatment Center, North Carolina, U.S.A. 
There has been intense interest in the pathogenesis of the early infection in the lung of cystic fibrosis (CF) infants. 
It is likely that early pathogenesis reflects the interplay between the abnormal airway epithelial ion transport 
consequent to loss of CFTR and bacterial colonization and infection. However, failure to fully understand the 
normal physiology of the liquids, i.e. ‘secretions’, that line airway surfaces severely impedes one’s capacity to 
understand how loss of CFTR functions adversely affects these activities. Two quite different hypotheses have 
been advanced to describe normal airway surface liquid (ASL) physiology and abnormal ASL in CF. In the 
‘hypotonic’ ASL hypothesis, normal airway epithelia extract salt but not water from ASL. In health, hypotonic 
ASL is speculated to render antimicrobial factors active, creating an effective ‘shield’ against inhaled bacteria. In 
CF, the Cl impermeability of airway epithelium, like the sweat duct, leads to a failure to extract salt, generating 
hypertonic ASL which inactivates antimicrobial factors and, consequently, permits chronic infection. In contrast, 
the ‘isotonic volume’ hypothesis predicts that normal airway epithelia absorb salt and water from airway surface 
to control ASL height and consequently normal mucociliary clearance. In CF, it is speculated that there is too 
little volume on airway surfaces so that mucociliary clearance is ineffective and mucus plugs obstruct small 
airways. Each hypothesis will be reviewed and the implications of each for pharmacotherapy and the use of 
‘surrogate markers’ for clinical trials focused on CF lung disease will be described. 
Gene therapy for cystic fibrosis 
E. ALTON 
National Heart & Lung Institute, London, U.K. 
Since the cloning of the cystic fibrosis (CF) gene in 1989, gene therapy has become a potential therapeutic option. 
This was first demonstrated to be successful in vitro (1,2) and, with the advent of CF animal models (3), the 
opportunity rose to test this in vivo. Two groups simultaneously reported that cationic-liposome-mediated human 
CFTR gene delivery to the lungs of CF mice was able to, at least in part, correct the basic abnormality in chloride 
transport (4,5). Although the author’s study demonstrated the feasibility of this, it is important to note there was 
marked variability in the degree of correction. Thus, some animals showed complete correction whilst others 
showed no change whatsoever. Importantly, no safety problems were encountered in either study. These and other 
studies of liposome-mediated transfer of reporter genes to non-human primates paved the way for human studies. 
On the basis of this animal work, a study of cationic-liposome-mediated gene transfer to the nasal epithelium 
of CF subjects was undertaken using the liposome DC-CHOL:DOPE (6). The study was of nasal applications 
because the nose also demonstrates the basic underlying ion transport defect and provides easier access, both for 
administration and for measurement. Finally, with regard to safety issues, it is clearly better to assess these in the 
mouse than in the lungs. Gene transfer was studied in 15 CF male subjects and of the common AF508 mutation. 
Male patients were studied because of the theoretical risk of gene transfer to the gonads, and since male CF 
patients are infertile, this would circumvent the problem. Subjects were divided into five groups of three. Three 
subjects were each given low dose (10 pug per nostril), medium dose (100 pug per nostril) of DNA and the relevant 
liposome controls received liposome equivalent to the 100 and 300 lug doses. The study protocol was double-blind 
and placebo controlled. The major goals were to assess safety and whether gene transfer could be achieved. With 
regard to safety, routine clinical parameters were studied, including radiographic changes and blood tests as well 
as lung function. A nasal biopsy was also taken on Day 4, the time at which maximal gene transfer was expected. 
Biopsy samples were studied in a blinded fashion by an experienced histopathologist. With respect to efficiency 
of gene transfer, vector-specific RT-PCR from the nasal biopsy (to assess whether the exogenous applied DNA 
had been transcribed to mRNA). Nasal potential difference measurements (a measure of the sodium and chloride 
abnormalities) were also assessed on each of the days when the patients were assessed. 
With respect to safety, there were no abnormal clinical events and no abnormalities on the chest X-ray or blood 
tests. Furthermore, there were no differences in the biopsy results between the placebo and CFTR-gene-treated 
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patients. With respect to efficacy of gene transfer, vector-specific PCR showed the presence of both DNA and 
messenger RNA in five of eight available biopsies in treated patients. With regard to the key parameter of 
functional correction, overall there was an approximate 20% increase in the chloride response on Day 3 following 
gene transfer (PcO.5) compared to baseline. This response completely disappeared by Day 7. Sodium-related 
correction, although seen, was less impressive than that of chloride. Certain subjects showed virtually complete 
correction or chloride responses whilst others showed none, in keeping with the variability noted in the animal 
studies. 
With regard to other liposome-mediated trials, three studies are currently underway, these being the 
Oxford/Cambridge/Manchester/Leeds group, the Edinburgh study and a study in Alabama U.S.A. The results 
from these are slowly emerging and will be presented as available at the meeting. 
With respect to CF, the impression is emerging that cationic liposome-mediated gene transfer is as efficient as 
adenoviral-mediated gene transfer (7-l l), at least to the nasal epithelium with regard to the key component of 
function correction of the basic ion transport defect. Again, with respect to the nasal epithelium, neither gene 
transfer system has appeared to produce a major safety issue. Liposome-mediated gene transfer to the lungs of 
humans has not yet been reported, although the author’s group will shortly complete such a study. Today, 
cationic-liposome-mediated gene transfer is relatively low as is also the case with other gene transfer systems 
currently studied. The level of gene transfer required in CF is unclear, but the suggestions indicate that gene 
transfer into 5% of cells in a monolayer or achievement of 5% of wild type messenger RNA levels in each cell may 
be sufficient, and the low levels of gene transfer thus far achieved with liposome-mediated gene transfer is 
approximately at this level. Whether these levels are sufficient for clinical effect and benefit remains unclear, but 
it is clearly important to move rapidly towards lung trials both for safety and for efficacy purposes. 
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Clinical issues in lung transplantation 
B. WHITEHEAD 
Great Ormond Street Hospital, London, U.K. 
Alton EWFW et al. Nature Genetics 1993; 5: 135. 
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Heart-lung transplantation was first performed in a patient with cystic fibrosis in 1985. Subsequent reports of its 
use in the adult population (1) encouraged the application of this procedure in the paediatric group (2). Since 
1988, children and adolescents with cystic fibrosis comprised the largest group (75%) referred for, and 
undergoing, heart-lung or lung transplantation at the Great Ormond Street Hospital for Children and this report 
is based on that experience. 
Patients referred for transplantation undergo a 2-3 day assessment. This is mostly undertaken on a daycare 
basis and involves clinical and psychosocial evaluation together with intensive education of patients and their 
families on all aspects of transplantation (3). Selection criteria include a life expectancy of less than 2 yr and a 
severely impaired quality of life. Clinical parameters used to guide decisions regarding placement onto an active 
transplant list include a Shwachman-Kulczycki score of less than 40, percentage of ideal weight corrected for 
height of less than 90%, FEV, <30%, 12-min walking distance ~800 m and oxygen saturation ~90% (3,4). Few 
absolute contraindications to transplantation now exist, although there will be increased risks in patients with 
previous thoracic procedures, including pleurodesis and pleurectomy, diabetes mellitus, those on corticosteroid 
therapy and those with liver disease. Colonization with Aspergillus and Burkholderia cepacia may also produce a 
less desirable outcome (5). Once accepted onto the active list for transplantation, optimum medical therapy 
should be maintained, including high standard nutritional support and aggressive management of intercurrent 
infections. Due to increased waiting times for acceptance to transplantation (over 12 months) and the attendant 
high attrition rate [over 50% (6)], intensive psychosocial support should be maintained for both patient and 
family. 
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Surgical techniques for heart-lung and, more recently, bilateral lung transplantation have been described (7,s). 
Post-transplant immunosuppressive therapy has not altered greatly over the past decade and most centres 
continue to use a triple immunosuppressive therapy maintenance regimen comprising cyclosporin A (Neoral), 
prednisolone and azathioprine. In addition to immunosuppressive therapy, specific attention to antibiotic 
prophylaxis and gastrointestinal management is mandatory. Monitoring of the lung graft comprises both 
non-invasive methods (pulmonary function testing, radiology, etc.) and invasive methods (bronchoscopy, 
bronchoalveolar lavage and transbronchial biopsy). Surveillance lung biopsies are no longer performed routinely 
but when clinically indicated (9). 
Current actuarial survival is 65% at 1 yr dropping to 34% at 5 yr. Survival does not appear worse in patients 
under 10 yr of age compared to older patients (10). The main cause for this reduced long-term survival is the 
development in most patients of obliterative bronchiolitis which is thought to be a form of chronic rejection (11). 
This disease often has an insidious onset l-2 yr after transplant, although may occur within months. It appears 
to have a higher incidence in children, and affected patients present clinically with dyspnoea, falling pulmonary 
function measurements and recurrent chest infections often associated with bronchiectasis. Treatment options are 
limited with retransplantation offering the only possible ‘cure’ but at high risk. Other complications are mainly 
related to long-term immunosuppressive therapy and include opportunistic infections, post-transplant lympho- 
proliferative disease, systemic hypertension and other steroid-related side-effects, Non-compliance to therapy, 
often a result of changes in physical appearance induced by immunosuppressive drugs, may lead to further 
deterioration of graft function. In conclusion, lung transplantation offers both children and adults with cystic 
fibrosis the opportunity of good quality short- to medium-term survival, although further breakthroughs in the 
prevention of obliterative bronchiolitis are required to improve long-term results. 
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The flora and fauna of CF airways 
J.R.W. GOVAN 
Department of Medical Microbiology, University of Edinburgh Medical School, U.K. 
Chronic bacterial colonization of the airways lading to intermittent episodes of debilitating pulmonary 
exacerbation and progressive lung damage are characteristic features of cystic fibrosis (CF) lung disease. The 
spectrum of microbial pathogens responsible is relatively restricted but continues to evolve in parallel with an 
increasing population of susceptible CF adults. Microbiological issues present diverse challenges to CF patients 
and their carers, and may begin with confusing and changing bacterial nomenclature. To microbiologists, 
Stenotrophomonas maltophilia (previously Pseudonomas and then Xanthomonas maltophilia) is a scientifically 
justified name to describe a newly recognized taxonomic species which exhibits limited nutritional ability but a 
predilection for maltose. To the CF community, the title might stimulate a vision of some microbial dinosaur out 
of Jurassic Park. However, as a multiresistant opportunist pathogen with a prevalence now reaching 30% in some 
CF centres (3), S. maltophilia may provide a glimpse of a future challenge in CF microbiology. 
The first evidence of a microbiological pattern to CF lung disease appeared in the historic 1946 paper by Di 
Sant’Agnese and Andersen (4). Post-mortem reports on 14 CF infants indicated that 12 of the 14 cases involved 
pulmonary infection by Staphylococcus uureus, and one case involved non-capsulated Haemophilus intuenzae. 
The remaining case involved one of the oldest infants (aged 32 months) who had been colonized by Bacillus 
pyocyanea, an organism later to become a major CF pathogen under its modern name. Pseudomonas aeruginosa 
(1,6,7). By the late 1990s improved management of CF has led to a much wider population of CF individuals and 
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an evolving spectrum of bacterial, viral and fungal pathogens, which includes mycobacteria, respiratory syncytial 
virus, Aspergillus jiimigatis and multiresistant bacteria. During the last decade, the problems caused by multi- 
resistant Gram-negative bacteria have been dramatically demonstrated by the emergence of Buvkholderia cepacia 
leading to segregation of B. cepacia-colonized individuals and other draconian forms of infection control (7,s). 
A highly adaptable soil inhabitant capable of using antibiotics as nutrients, B. cepaciu, was previously best 
known as a plant pathogen. The emergence of B. cepacia in the CF population presents three new microbial 
challenges: first, innate multiresistance to most antimicrobial agents; second, the ability for epidemic spread 
between CF patients in hospital or through social contacts; and third, the risk of unexpected and rapidly fatal 
pneumonia and septicaemia in approximately 20% of colonized individuals including those with relatively mild 
CF disease. Epidemiological studies on this unusual bacterium (B. cepacia possesses multiple chromosomes and 
a genome twice the size of Eschevichiu coli) have identified epidemic markers in highly transmissible strains which 
have spread throughout the U.K. and North America including unusual giant cable pili which act as adhesins for 
epithelial and mucin receptors and DNA sequences whose function is unclear. Immunological studies have 
clarified some of the host/bacterial factors responsible for B. cepacia virulence, in particular neutrophil-mediated 
inflammation (8). Finally, state-of-the-art taxonomic analyses are helping with difficulties in the laboratory 
identification of B. cepacia, in particular clarification of the complex relationships between isolates presently 
identified as B. cepacia but which comprise at least five bacterial species (13). Burkholderia cepacia research merits 
high priority, not only in the context of CF lung disease but to provide scientific evidence for assessment of the 
human hazards associated with the imminent agricultural exploitation of B. cepacia as an antifungal and 
crop-promoting biopesticide (8). 
Whilst the CF community faces the challenge of an expanding spectrum of potential pathogens (6,7), other 
forms of microbiological research continue to reveal important new information on the epidemiology and 
regulation of virulence in P. aeuuginosa, and the links between the functioning of CFTR as a chloride channel, 
the advantages of the CF carrier status and susceptibility of the CF lung to microbial infection. 
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The DNase experience 
A. BUSH 
Royal Brompton Hospital, London, U.K. 
HISTORICAL BACKGROUND 
The pulmonary damage of cystic fibrosis (CF) is characterized by chronic infection, sputum production, and 
ultimately bronchiectasis, car pulmonale and death (1). Important in the pathogenesis is the accumulation and 
persistence of viscous purulent secretions in the airways. Strategies to improve lung function include vigorous 
antibiotic usage and chest physiotherapy to clear secretions. For more than 40 yr it has been appreciated that the 
main reason for the increased viscosity of sputum was deoxyribonucleic acid (DNA) predominantly from 
degenerating host polymorphs, but also from bacteria (2). Indeed, it is an inherent property of DNA to form 
thick, viscous gels (3). Addition of DNA to sputum in vitro increases viscosity (4). The sputum of CF patients 
contains up to 0.3 mg ml - ’ DNA, as much as three times more than sputum from patients with other causes of 
bronchiectasis (4,5). Early in vitro (6) and in vivo (7) work with bovine DNase demonstrated that sputum viscosity 
was reduced and lung function improved when patients with acute or chronic lung suppuration (8), including CF 
(9), were studied. However, the preparations then available were contaminated with bovine trypsin 1.1 pug mg - ‘) 
and chymotrypsin [22 pug mg ~ ’ (lo)], and were associated with rare but serious allergic reactions, including 
bronchospasm, and their use was discontinued. Only with the isolation and cloning of the purified human enzyme 
has long-term DNase therapy in CF become practicable. 
A.56 ABSTRACTS 
HUMAN DNASE: EARLY IN VITRO STUDIES 
In 1990, Shak et al. reported the isolation of human DNase (12). This is a 260 amino acid protein, molecular 
weight 29 300 kDa. There is approximately 77% homology with bovine DNase- 1, with both proteins having four 
cysteine residues at positions 101, 104, 173 and 209, two potential N-linked glycosylation sites (amino acids 18 
and 106) and a conservated histidine at the active site (amino acid 134). Two six-stranded P-pleated sheets are 
packed against each other to form the core of the protein, which is surrounded by eight a helices and six turns. 
The enzyme requires the divalent cations calcium and magnesium for optimum activity, and works best at neutral 
pH; it is inhibited by heat and the protein actin. The reported sputum concentrations of calcium and magnesium, 
and sputum pH are adequate for DNase to be active. In vitro studies showed that catalytic amounts of human 
DNase (8 pug ml- ‘) greatly reduced the viscosity of purulent CF sputum, converting it from a non-flowing 
viscous gel to a flowing liquid (21). No significant effects in this ‘pourability’ assay were shown with lysosomal 
DNase-II, RNase A, trypsin, chymotrypsin, or with the vastly over-popular N-acetyl cysteine. 
EARLY DOSE-FINDING AND SAFETY STUDIES 
Hubbard et al. (13) compared three dose regimes (20 mg once daily, 20 mg twice daily and 10 mg three times per 
day) in 16 patients with CF whose mean pretreatment forced vital capacity (FVC) was 53 * 4% predicted. Aitken 
et al. (14) studied 12 normal volunteers and 14 patients with CF whose FVC was above 40% predicted prior to 
treatment, using doses of 2, 6 and 10 mg three times a day. Both groups found an approximately 10% 
improvement over baseline in first second forced expired volume (FEV) and FVC in these CF patients. The drug 
was well tolerated, with minimal rises in serum DNase levels (3 & 2 ng ml - ’ rising to 5 + 2 ng ml- ’ 6 h after 
treatment). No anti-DNase antibodies were detected, and there were no significant side-effects. 
EARLY EFFICACY STUDIES 
The first published study was of 71 adults, of whom 36 received DNase and 35 placebo (15). All patients had 
a FVC above 40% predicted. There was a statistically significant increase over baseline in FEV (13.3%) and 
FVC (7.2%). The benefit was lost within days of stopping treatment, but was maintained if treatment was 
continued. A further study, also conducted in a double-blind parallel manner, of patients with moderately 
impaired pulmonary function (FVC between 40 and 70% normal) showed an improvement in FEV and FVC 
of around 10P15% and l&12%, respectively, within 14 days of starting treatment. This effect rapidly returned 
to baseline within a few days of stopping treatment. There was some suggestion that the more severely affected 
patients in this study derived greater benefit from treatment (16). A phase 3 study involving 968 CF patients 
has shown that where rhDNase is given for 6 months (7), improvement in lung function is sustained over the 
period of administration. A single dose of 2.5 mg day - ’ was as good as twice daily. The benefits were of less 
magnitude than in the phase 2 studies (FEV increase by about 5.5%). About one-third improved their FEV by 
more than 10%. Subsequently, it has been shown that improvement is maintained over 2 yr of open label 
treatment (18). There have been two studies in severely ill CF patients (FEV 40% predicted). A British study 
(19), double-blind parallel group of 70 patients, showed no significant difference between placebo and 
rhDNase after 2 weeks. This study contuined as an unblinded protocol with all patients going on to receive 
rhDNase for 6 months. There was an improvement in lung function which reached a peak at around 3 months 
into treatment of about the same order as that in the previous studies. However, the absence of continued 
blinding in the extended phase of this trial substantially weakens the conclusions. In an American study (20), 
320 patients were studied double blind for 12 weeks; the DNase group improved significantly (PcO.01) 
compared with placebo for FEV (9.5 vs 2.1%) and FVC (12.4 vs 7.3%). In all studies, the benefits of rhDNase 
were lost within days of stopping treatment. All studies reported fairly wide 95% confidence limits for 
improvement, implying that some individuals appear to derive very great benefit and some virtually none. A 
further secondary endpoint in these trials was a reduction in infective exacerbations and days spent in 
hospital. It is known that DNA co-precipitates with some aminoglycosides. Hence, the reduction in sputum 
volume and DNA content may be the mechanism whereby infection is reduced, particularly in patients taking 
inhaled aminoglycosides (17). Indeed, there were early suggestions that DNase and antibiotics may be 
synergistic (8). It should be noted that the average reduction in hospital days was of the order of 2 days per 6 
months, which is not dramatic (20). This sort of quality-of-life questionnaire also demonstrates improvement 
during treatment with rhDNase. 
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One study reported the use of rhDNase at the time of an acute exacerbation, in combination with the usual 
measures of intensive physiotherapy and intravenous antipseudomonal antibiotics. Unfortunately, no additional 
benefit was shown (22). 
The author’s group have retrospectively reviewed their experience of rhDNase in 65 children (23). About 
one-third of the group had a sustained improvement (FEV or FVC >20% above baseline) after 1 yr of treatment, 
but one-third actually deteriorated. The response at 3 months was strongly predictive of the response at 1 yr, but 
the author’s group and others (23-25) have been unable to predict in advance whether an individual patient will 
respond; a therapeutic trial in appropriate patients is the only way to find out. It is essential that objective 
measurements are used; many of the author’s patients who deteriorated actually said they felt better. This is a 
very difficult group with which to deal. 
In all studies to date, there have been few if any side-effects, and certainly no major harm, despite use in very 
sick patients. Problems encountered have included pharyngitis and voice alteration. Rarer side-effects have 
included facial oedema and transient falls in FEV after the administration of rhDNase. There has been no 
evidence of allergic reactions, and the development of IgE antibodies to rhDNase is very rare. It would seem that 
it is a very safe medication even in very sick patients. 
METHODS OF ADMINISTRATION 
As with all nebulized medication, the delivery system is important. Ultrasonic nebulizers should not be used, 
because they denature and thus inactivate the rhDNase. Due to the physical properties of the solution: rhDNase 
must not be mixed with any other nebulized drug, and must therefore be given separately. Fiel et al. compared 
three different jet nebulizers, all of which were equally good (26). Shah et al. compared the Sidestream/CRSO with 
the Hudson/Pulmo-Aide; clinically they were equally effective, but the former was quicker to use, a point of not 
inconsiderable importance in clinical practice (27). 
DOES RHDNASE WORK: WHAT END-POINTS SHOULD BE USED? 
The main criticism of the studies described above is that they have relied on surrogate end-points such as lung 
function, and not shown an increase in survival. Currently, survival curves are so flat (28) that it would be an 
immense endeavour over many years in thousands of patients to show reduced mortality with any treatment. It 
must be conceded that there is only a loose relationship between lung function and survival. There is also 
considerable controversy about what is a significant change in lung function. For example, a 20% increase in FEV 
sounds impressive, but if the baseline is 350 ml, this is within the noise of the measurement. The natural 
variability of lung function in CF is not inconsiderable (coefficient of variation for FEV and FVC 15-20%) (29). 
This is particularly true for indices of flow at low lung volumes (coefficient of variation >30% (29). It is also 
important to distinguish between group changes (which may be clinically insignificant) within which there may 
be individuals who show dramatic benefit. 
Another popular end-point is measurement on sputum in vitro. Viscosity is reduced (30), but the relevance of 
any such measurement to the complex branching structures of the airway in vivo is highly dubious. Indeed, it may 
be possible to reduce the sputum viscosity to a point where clearance is actually impaired (31). Treatment has 
been shown to reduce the concentration and size of extracellular DNA in sputum (32). Other sputum end-points 
used include the reduction of neutrophil elastase, a mediator prominently implicated in the pathogenesis of CF 
lung disease (33), and the chemokine IL-8, the major neutrophil chemoattractant (34,35). These correlate with 
any in vivo benefit. In concluding this section, it should be noted that the evidence for benefit, however much it 
is criticized, is based on the largest trials ever performed in CF. 
CURRENT POSITION 
rhDNase is now available on general prescription, It is licensed for CF patients aged over 5 yr, with FVC greater 
than 40% predicted. In considering who should be offered this treatment, clinical and fiscal issues arise. These are 
important in different ways, and should be considered completely separately initially. There are two major clinical 
issues that are likely to arise in deciding whether an individual should go on treatment. Another nebulized 
therapy imposes an extra time constraint on patients. Second, as with all new preparation, the risk of side-effects 
must be considered. This would appear to be small, but can never be considered to be zero. 
The fiscal issue centres around cost, which is around 27500 per patient per year. Potentially, the U.K. CF drug 
bill could rise by &50 million per annum. What is essential is that clinicians distinguish rationing on financial 
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grounds from rationing on clinical grounds (i.e. the drug is inappropriate for a particular patient). Financial 
rationing must be honest and open. 
So who should on clinical grounds be offered a trial of rhDNase? In the >5 yr age group, a trial of 
rhDNase should be at least considered, excluding those with FEV and FVC above some arbitrary level (e.g. 
two standard deviation scores below the mean for their height) (36). rhDNase has been used safely in the very 
ill so a lower limit of lung function to exclude potential candidates does not seem logical. Those who are 
non-compliant are excluded on clinical grounds, in that they may actually deteriorate on rhDNase (below). 
Some relatively well patients will wish not to undertake an inconvenient and time-consuming treatment. There 
are no other contraindications from the published literature; any other rationing is on financial grounds, and 
this should be overtly stated. The dose is 2.5 mg daily for 3 months (based on the maximum time for a 
response to be seen in the seriously ill group). If there is no significant improvement, as judged on lung 
function criteria (principally spirometry), then the dose may be increased to 2.5 mg twice daily for a further 3 
months. This requires very careful consideration and monitoring. If there is still no improvement, then the 
medication should be discontinued. rhDNase should be given after a session of physiotherapy, and when first 
used, may increase the requirement for physiotherapy. It is not a substitute for physiotherapy, and indeed has 
actually worsened the position of those whose physiotherapy techniques are less then diligent. It should be 
noted that even in those who do physiotherapy enthusiastically, transient deterioration may be noted within a 
few days of starting rhDNase, and an admission to hospital for intensive treatment including intravenous 
antibiotics may be needed. 
ALTERNATIVE THERAPIES 
Although it has been suggested that bovine DNase should be reinvestigated (37) this is unlikely to be done 
because of the risks of side-effects. There is no likely alternative to the human recombinant product. A different 
approach is to try to break down other sputum components which contribute to the elevated viscosity. Actin 
filaments are known to be present in CF sputum (38,39), and preliminary work has been carried out using 
gelsolin, a protein that rapidly severs non-covalent bonds between monomers within a filament (38). In vitro work 
showed a marked decrease in sputum viscosity. There is as yet no in vivo work. Another in vitro study suggested 
that the combination of rhDNase and N acetylcysteine might be additive (40). 
Another and much cheaper avenue is hypertonic saline, routinely used by physiotherapists to aid expectora- 
tion. The changes in lung function (an increase in FEV of 15% compared with 2.8% on placebo), at least in the 
short term, are comparable to those obtained with DNase (41). 
CURRENT MAJOR ISSUES 
There is a Syren cry in current circles that rhDNase should be offered to all patients, even those with early stage 
disease (42). The argument runs that there is evidence of inflammation and increased DNA in bronchoalveolar 
lavage in even very young, asymptomatic babies (4345), and this DNA can and should be cleared using DNase. 
There is no evidence as yet that early use of DNase is beneficial; indeed, in no study has it been shown that the 
use of placebo prior to starting DNase prejudiced the lung function response. Indeed, remembering that the first 
3 yr of life are a period of profound alveolar multiplication, the effects of DNase on which are totally unknown, 
then caution is certainly necessary in the very young. 
The financial cost of this medication is formidable. It is quite clear that only some of the cost of DNase can 
be recouped on savings on antibiotic costs (23,46,47). Granted that rationing of resources is inevitable for the 
foreseeable future, is 230 000 best spent on an expensive treatment for four individuals, or say on hiring a home 
care nurse who may benefit the whole clinic? I do not profess to know the answer to this question, but it will not 
go away. 
CONCLUSIONS 
rhDNase is a major advance in the treatment of CF, which will significantly improve the lung function of 
one-third of children. It is not a panacea; some will not respond, and it will not ultimately halt the relentless 
progression of the disease. Used responsibly, rhDNase will benefit many with CF, in some cases very 
dramatically. The key will be controlled therapeutic trials, continuing the medication only in individuals who 
show clear benefit, but not allowing it to become the world’s most expensive placebo in those who do not. 
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FURTHER READING 
The reader is referred to three very important review articles (48-50) from different perspectives. Together they 
paint a reasonably balanced picture, but the enthusiasms and doubts of the different authors need careful 
blending! 
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Current approaches in physiotherapy 
J. A. PRYOR 
Royal Bvompton Hospital, London, U.K. 
‘As soon as a patient is diagnosed as having cystic fibrosis, both the patient and their relatives should be taught 
how to perform chest physiotherapy’ (1). Physiotherapy can help with the problems of excess bronchial 
secretions, reduced exercise tolerance, breathlessness, chest wall stiffness and pain of musculoskeletal origin. 
Treatment regimens currently differ within countries and among countries. 
EXCESS BRONCHIAL SECRETIONS 
When cystic fibrosis is diagnosed in infancy, most paediatricians recommend introducing physiotherapy at this 
time in an attempt to delay the destructive process of infection and fibrosis. If physiotherapy becomes an accepted 
part of life, compliance will probably be better than if physiotherapy is introduced at a later stage. 
For the infant, physiotherapy is passive with the use of positioning, chest clapping and chest vibrations, but 
even at a young age, treatment should be fun and laughing will also stimulate coughing. Infants with cystic 
fibrosis have a higher incidence of gastro-oesophageal reflux, but there is conflicting evidence as to whether this 
is exacerbated by positioning with physiotherapy, especially the head-down positioning (2,3). 
From the age of about 2 yr, ‘huffing’ games can be started and by the age of 8 or 9 yr the child can begin to 
do some of the treatment himself and gradually learn to be independent of his parents for periods of time. Most 
adolescents prefer to take responsibility for their own physiotherapy, but assistance with treatment is often 
appropriate during an exacerbation of infection and for patients who are too frail to manage on their own. 
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Different techniques for airway clearance have developed independently in different parts of the world. The 
most widely recognized are the active cycle of breathing techniques, positive expiratory pressure (PEP), autogenic 
drainage, oscillating PEP (Flutter) and postural drainage and percussion. Many of these regimens now include 
the forced expiration technique of the active cycle of breathing techniques, and this has increased the efficiency 
of these regimens. 
There is some evidence-based practice, but must of the literature is conflicting and confusing. Regular 
assessment and re-assessment of the individual is essential to optimize treatment regimens which will vary from 
patient to patient and may vary from treatment to treatment. The use of gravity-assisted positions is not always 
essential. 
Inhalation therapy is often an integral part of a physiotherapy treatment regimen. The time of inhalation 
in relation to the airway clearance techniques needs to be considered, together with the type of neubulizer and 
its driving gas (5). Regular cleaning and thorough drying of the equipment is essential to minimize bacterial 
growth (6). 
The optimal time for the administration of Pulmozyme (DNase) in relation to physiotherapy has not yet been 
identified and needs to be assessed for each individual. Some patients benefit most by inhaling it about 30 min 
before physiotherapy for airway clearance. Others find it takes several hours to reach a maximal effect and take 
it after one physiotherapy session with the result that the next session is more productive. 
Hypertonic saline (7) may be inhaled before physiotherapy to assist in clearance of secretions. Aerosol 
antibiotics should be inhaled after secretions have been cleared to obtain maximal benefit. 
REDUCED EXERCISE TOLERANCE 
Exercise should play an important part in the management of cystic fibrosis to improve general physical fitness 
and muscle strength. It has been shown to improve cardiovascular fitness and muscle endurance (8), to reduce 
breathlessness (9) and to improve self esteem and promote a feeling of well being (10). 
Exercise increases mucociliary clearance, but is less effective in the clearance of bronchial secretions than the 
active cycle of breathing techniques (11). Children should take part in normal school games when possible, and 
adults should be encouraged to take some form of enjoyable exercise regularly. 
In patients with advanced pulmonary disease who desaturate during exercise, supplemented oxygen has been 
shown to increase exercise tolerance and aerobic capacity, and it can reduce exercise-related arterial oxygen 
desaturation (12). 
Exercise programmes should combine endurance exercises for aerobic fitness and muscle strengthening 
exercises. 
BREATHLESSNESS 
The use of positioning and breathing control can help to reduce breathlessness, and the use of breathing control 
while walking up stairs and hills can help to improve exercise tolerance (13). 
Non-invasive positive pressure ventilation may be of benefit to correct hypoxaemia during periods of acute 
pulmonary deterioration (14). It may also be used as a bridge to transplantation (15). 
CHEST WALL STIFFNESS AND PAIN OF MUSCULOSKELETAL ORIGIN 
The alterations in chest wall mechanics develop as a consequence of an increase in the work of breathing and 
hyperinflation of the chest leading to a shortening of the accessory muscles of respiration. Posture and trunk 
mobility exercises should be encouraged to maintain flexibility of the thoracic cage. Chest wall stiffness and pain 
are not uncommon complications. Manual therapy techniques may increase thoracic mobility and may improve 
lung function (16). The pain may respond to treatment by manual therapy, transcutaneous electrical nerve 
stimulation or acupuncture. 
HEART-LUNG TRANSPLANTATION 
The physiotherapist also has a role both before and after heart-lung or lung transplantation. Before 
transplantation, the patient’s exercise ability will be very limited but an exercise programme, often oxygen, 
should be undertaken to optimize muscle strength and cardiovascular function. Postoperatively, an intensive 
rehabilitation programme is essential to gain maximum benefit and improved quality of life (17). 
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With the loss of the cough reflex and impaired mucociliary clearance following transplantation, early 
recognition of signs of a chest infection is important to minimize granulation tissue formation in the region of the 
large airway anastomosis and pooling of secretions in the transplanted lung which may lead to bronchiectasis 
(18). It is therefore recommended that a short session of physiotherapy for airway clearance be continued on a 
daily basis, and increased as necessary during periods of chest infection. 
TERMINAL CARE 
As physiotherapy is an integral part of the life of those with cystic fibrosis, it is important for a physiotherapist 
to continue to provide support in the terminal stages and this, in addition to assistance with modified airway 
clearance regimens, may include positioning to make the breathless patient as comfortable as possible. 
COMPLIANCE 
Carr et al. (19) asked people with cystic fibrosis about their views and beliefs on chest clearance and exercise. Fifty 
people responded and 100% agreed that physiotherapy was helpful when they were well. Ninety percent agreed 
that physiotherapy would prevent their chest from deteriorating. Adherence to treatment is influenced by the 
patient’s knowledge and understanding of his condition (20) and in the context of physiotherapy, by agreed and 
realistic treatment regimens. 
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New modalities for the treatment of lung infection in cystic fibrosis: human 
recombinant antibody therapy 
G. l? RIGG 
University of Manchester, U.K. 
In cystic fibrosis patients, Burkholderia (formerly Pseudomonas) cepacia and Pseudomonas aeruginosa are major 
pathogens. Both organisms also cause nosocomial infections, and are frequently associated with contaminated 
fluids (including water supplies, antiseptics and irrigation lines). P. aeruginosa is the major cause of morbidity and 
mortality in children with cystic fibrosis (CF), causing bronchiectasis and progressive obstructive airways disease, 
the rate of colonization rising with age. The need for long-term antibiotic treatment in chronically colonized CF 
patients has lead to the emergence of resistant strains, a critical situation since anti-pseudomonal antibiotics are 
limited. B. cepaciu occurs in 10 (U.K.) to 40% (U.S.A.) of CF patients. It has achieved notoriety because of its 
ability to cross-infect and cause an accelerated decline in pulmonary function. It is virtually untreatable, being 
highly resistant to most antibiotics, even those effective against P. aeruginosa. Recent advances in antibody 
engineering have made therapeutic use of genetically engineered antibodies an achievable objective. Unlike serum 
therapy (which was widely used before antibiotics became available in the 194Os), such antibodies can be 
produced economically in bulk quantities without the risk of contamination by human retroviruses or serum 
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sickness. Due to their small size, they show improved penetration of tissues and can be constructed without the 
Fc region which interacts with complement and cells of the immune system and can cause adverse inflammatory 
reactions. To this end, the author’s group have constructed human recombinant antibody libraries for the specific 
purpose of selecting and over-producing antibody molecules capable of neutralizing bacterial infection. This has 
been achieved by using polymerase chain reaction to amplify human V, and V, antibody variables domains. 
These gene fragments were assembled in phage display cloning vector pCANTAB5 for expression as single chain 
variable fragments (scFv) consisting of antigen binding sites (complementarity determining regions (CDRs) 
expressed at the surface of the Ml3 bacteriophage. This approach permits screening for scFv capable of binding 
bacterial antigen, and will allow over expression of scFv as well as genetic modifications such as addition of toxin 
domains or complement binding regions for improving bacterial killing. The author’s group has previously 
defined targets for recombinant antibody therapy by examining antibody responses in patients with severe 
infection and correlating recognition of particular antigens with survival (1,2). Porin OpcP2 of B. cepacia and 
porin F of P. aeruginosa were identified and chosen as targets. Additional targets for screening include outer 
membrane antibiotic resistance determinants from B. cepacia and P. aewginosa as well as LPS lipid A-core 
components. It is hoped that by targeting antibiotic resistance mechanisms through stearic interactions of scFv, 
these bacteria will be rendered susceptible to existing treatment regimes. Antigen targets will be purified using 
gene fusion and biochemical techniques, and used to screen for specific phage display antibodies. The therapeutic 
potential of recombinant antibodies will be assessed by their ability to inhibit bacterial growth using in vitro 
biofilm assays both alone and in combination with antibiotics. 
FURTHER READING 
Matthews RC, Burnie JP FEMS Imm Med Micvobiol 1994; 9: 1-6. 
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The neutrophil and the CF lung 
J. 0. WARNER 
University of Southampton, U.K. 
A host of immunological abnormalities have been described in cystic fibrosis, the frequency of which increases as 
the disease itself progresses. None of the defects, however, have explained the susceptibility of the cystic fibrosis 
patient’s airways to infection. Suffice it to say the primary defect leads to excessive bacterial infection in the 
respiratory tract. This in turn produces a host of abnormalities which have their final common pathway through 
the effects on neutrophils. There is a growing body of evidence that the consequences of neutrophil activation in 
the infected airways are at least partly responsible for the escalating lung damage leading to respiratory failure 
and death. Thus, study of the pathways leading to neutrophil activation will help to identify potential therapeutic 
targets to delay or prevent the evolution to respiratory failure (1). 
IMMUNE HYPER-RESPONSIVENESS 
The continuous antigenic stimulation produced by persistence of organisms in the airway leads to a chronically 
overactive immune response. The polysaccharide of the organism stimulates their phagocytosis by alveolar 
macrophages which re-present the antigenic fragments via MHC II molecules together with a range of cytokines 
to activate helper T-lymphocytes. The T-cell in turn produces interleukin-2 and expresses interleukin-2 receptors 
which leads to proliferation of the T-cell and elaboration of a large number of other cytokines leading to 
recruitment of a range of other inflammatory cells including eosinophils and, most importantly, neutrophils. 
Furthermore, via its cytokines, the T-cell also orchestrates the gene deletional switching from IgM to IgG and 
IgE production by B-lymphocytes. Thus, as the disease advances, it is possible to demonstrate ever increasing 
levels of both IgG and IgE, though these changes tend to occur late in the disease process (2). More recently, it 
has been shown that levels of a soluble component of the interleukin-2 receptor as a reflection of T-cell activation 
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are raised in the serum of children with cystic fibrosis and this occurs very early in the evolution of the disease, 
being sometimes found in very young children with cystic fibrosis who have no evidence of active lung 
involvement (3). 
NEUTROPHIL ACTIVATION 
One of the most potent cytokines to promote chemotaxis and activation of neutrophils is interleukin-8. This 
cytokine is elaborated by a large number of cells within the airways including alveolar macrophages and 
bronchial epithelium. Very high levels are found in sputum and bronchoalveolar lavage from patients with cystic 
fibrosis, and there is a good correlation between levels and disease severity (4). The author’s group have also 
shown that treatment with antibiotics leads to a progressive reduction in the levels of interleukin 8 in the sputum. 
However, this is not associated with such a dramatic fall in neutrophil numbers. It would appear that they remain 
within the airways even when there is a diminished bacterial load. Apoptosis of the neutrophils is impaired and 
they consequently eventually disrupt releasing elastases which contribute to the lung damage as the quantities are 
in gross excess of overcoming local inactivation processes. Interleukin-10, which is constitutively expressed and 
produced by bronchial epithelium, inhibits the synthesis of interleukin-8 and there is some evidence that this is 
impaired in cystic fibrosis (5). Whether or not this latter defect is primary or secondary remains to be established. 
However, it facilitates the final common pathway to lung damage and the cleavage of lung elastin by neutrophil 
elastase. Indeed, the presence of urine elastin degradation products in the urine of CF patients correlates well 
with severity of disease (6). 
It is important, however, to also note that there are many other neutrophil activating products in the airways 
which are increased in cystic fibrosis, including complement activation products such as C5a, as a result of 
antibody antigen complexing, and the organisms themselves release a chemotactic factor (fMLP) while 
leukotrienes, platelet activating factor and other mediators have chemotactic properties and are also increased. 
NEUTROPHIL FUNCTION 
Having elaborated on the factors which trigger neutrophil responses, it is also important to understand some of 
the intrinsic functions of the neutrophil itself. In the latter stages of cystic fibrosis, it is common to find both 
neutrophils and macrophages in the airways containing organisms which have not been effectively killed. This 
occurs particularly in response to Pseudomonas aeruginosa (1). The author’s group have recently demonstrated 
that the neutrophils from children with cystic fibrosis have an impaired capacity to generate an oxidative burst 
which would be associated with organism killing. This defect is greatest in patients with active infection and is 
correlated with abnormalities of neutrophil cell membrane phospholipids. The capacity of the neutrophils to 
respond to organisms by phagocytosis is only very marginally impaired with a slightly delayed recruitment of 
cells compared with normals. This is particularly apparent during active infection. Thus, just at the time when the 
neutrophils are most needed to eliminate organisms, they seem to work least efficiently. To what degree this is due 
to a downregulation of responses to ligand by receptors which have been over stimulated by massive release of 
such cytokines as interleukin-8 remains to be established. It will also be interesting to speculate on whether some 
of the local opsonizing factors in the airways might also be deficient. This is particularly important in relation to 
surfactant proteins and will be discussed in an accompanying presentation by Dr. Postle. 
THERAPEUTIC INTERVENTION 
Insights into the role of the neutrophil both in controlling infection and in contributing to lung damage certainly 
have major implications for approaches to therapy. Currently, the main focus of treatment is on suppression of 
the organisms with antibiotics and attempts to improve clearance from the respiratory tract. However, 
modulation of the immune responses is an attractive alternative approach. 
In respect of clearance of organisms, a relatively new therapeutic modality now being used in increasing 
quantities is DNase. In a collaboration between Child Health and University Medicine in Southampton, the 
author’s group have shown that interleukin-8 is bound to DNA as well as actin in sputum. The addition to 
DNase to CF sputum cleaves interleukin-8 from DNA while Gelsolin cleaves it from actin. This increases its 
biological activity and might therefore risk increased inflammation. These effects need now to be investigated in 
detail in vivo. 
There are intriguing benefits from the use of a number of anti-inflammatory drugs including corticosteroids, 
non-steroidal anti-inflammatories and even methotrexate and cyclosporin. The advent of recombinant 
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a,-antitrypsin will also have considerable interest to those treating children with cystic fibrosis (7). Many other 
approaches such as anti-interleukin-8 antibodies, recombinant surfactant proteins and interleukin-10 will also 
need to be investigated. 
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Bronchial lavage in monitoring CF 
G. CONNETT 
Department of Paediatrics, Southampton University Hospital Trusts, U.K. 
Bronchoscopy is a procedure very much favoured by bronchoscopists. Apart from its use in satisfying the 
interventional desires of the respiratory specialist, it also facilitates direct study of the lower respiratory tract by 
the research scientist. The role of bronchoscopy and analysis of bronchoalveolar specimens in aiding the cystic 
fibrosis (CF) physician’s care of his or her patients has not yet been clarified. Unfortunately, like most existing 
therapies for CF, its value is unlikely to be scrutinized by randomized controlled trials. Despite this, published 
studies do indicate that bronchoscopy can identify unsuspected problems and provide useful prognostic and 
aetiological information to the direct benefit of the individuals undergoing the procedure. 
Historically, bronchoscopy was first introduced into CF care as a therapeutic procedure (1). Large volume 
lavage was used to try and clear diffuse mucoid impaction, and selective aspiration of mucous plugs or secretions 
was used to try and resolve lobar or segmental atelectasis. Whilst manifest benefits are achievable and widely 
appreciated by the patients concerned, these are rarely sustained in those with moderate or severe lung 
involvement (2). Early intervention in relatively well patients with new atelectases, persisting despite intensive 
antibiotics and physiotherapy, are more likely to be of benefit. In such cases, lung re-expansion and the 
prevention of irreversible lung damage is more likely. The use of rhDNase at the time of bronchoscopy might 
help loosen and dislodge areas of mucous plugging. The only other major therapeutic role of bronchoscopy is in 
the management of massive haemoptysis where it might usefully identify the site of bleeding prior to pulmonary 
artery embolization (3). 
In recent years, the emphasis on the role of bronchoscopy has shifted away form heroic rescues in those with 
severe complications towards better targeted pre-emptive strikes in those who are well to try and maximize their 
chances of staying healthy. The mechanisms underlying the initiation and progression of lung disease in CF are 
still poorly understood but bronchoscopy studies in cases identified through newborn screening programmes have 
proven that neutrophil-dominated inflammation begins in the neonatal period (4). Longitudinal data indicates 
that upregulation of cytokine expression occurs at least as early if not prior to the onset of infection and is 
sustained, increasing exponentially whenever bacterial pathogens are cultured in bronchoalveolar lavage fluid 
(BALF) and reducing after treatment with antibiotics (5). Clearly for any sort of immunopharmacological or 
antimicrobial intervention to have maximum effect, it needs to be started soon after birth. The early use of 
anti-inflammatory therapies, particularly those targeting neutrophil elastase inhibition, would seem reasonable, 
but safety and efficacy trials are still awaited. The data also supports a more aggressive approach to antimicrobial 
therapies. This would seem reasonable based on current understanding of the benefits of antibiotics in CF, but 
the technology is now available to be more critical and specific in our approach rather than relying on empirical 
measures and indirect information. 
It is absolutely clear that the concept of chronic colonization with intermittent acute exacerbations of infection 
should be abandoned. Cystic fibrosis lungs are subjected to a continuous onslaught of proteolytic destruction. It 
is quite possible and indeed likely that much of the lung destruction in CF occurs between acute exacerbations 
of respiratory symptoms (6). The presence of CF pathogens in the lower respiratory tract are the single most 
important factor associated with this disease process. Unfortunately, those infants who have CF pathogens and 
evidence of increased lung inflammation in their lower airways are not distinguishable on clinical grounds in the 
early stages of the disease process (6,7). Insidious lung damage advances considerably, well before the 
development of respiratory symptoms and changes in lung function. Is it right therefore to be more assiduous and 
monitor CF patients with regular bronchial lavage? 
ABSTRACTS A.65 
It is self evident that the single most important indicator of when antibiotics should be prescribed is when there 
is evidence that pathogens are infecting the lower respiratory tract. What is less clear is the validity of easily 
obtainable evidence to suggest that this is occurring. It is worthwhile considering the accuracy of alternative 
specimens in predicting lower respiratory infection. Sputum samples reliably indicate whether lower respiratory 
pathogens are present and can also be analysed to determine levels of inflammatory disease activity. Given good 
care, however, most young CF patients should not be regularly productive and such specimens are rarely 
available. Induced sputum after inhalation of hypertonic saline is a useful technique but is not consistently 
effective and most children aged less than 7 yr will either refuse to co-operate or swallow the specimen. In most 
cases, current practice in non-sputum producers is to rely on oropharyngeal (OP) cultures (cough swabs) to try 
and predict the presence of lower airway pathogens. It has been argued that OP cultures do not reliably indicate 
the presence of pathogens in the lower airways of CF children. Published studies show that the sensitivity of OP 
cultures for detecting P. aeruginosa in the lower respiratory tract is around 70% with a specificity of greater than 
90% (7,s). For S. aureus, the sensitivity is 86% but specificity is reduced to 61%. High numbers of false positive 
results cause poor predictive values of around 50%. Furthermore, genetic fingerprinting of organisms from the 
upper and lower respiratory tract indicates that even where there is agreeance in the species isolated, the 
organisms are often unrelated (7). The data from this and other studies suggests that basing treatment on OP 
cultures alone commonly leads to under- and/or overtreatment of lower respiratory infection on a somewhat 
empirical basis. Many of the children reported in the largest study had acute respiratory symptoms at the time 
of bronchoscopy. It is quite likely that thee will be even poorer agreeance between the results of upper and lower 
respiratory specimens when looking for evidence of asymptomatic infection. Additional measurement of serial 
antibody responses to P. aeruginosa might help to avoid late diagnosis of infection with this organism. However, 
when antibody levels are elevated and OP cultures are negative, bronchoscopy would seem essential. 
BAL specimens provide a gold standard for microbiological diagnosis. With the additional information about 
levels of cellular and cytokine inflammation, they provide a useful indicator about the extent to which protocols 
such as the continuous use of flucloxacillin are effectively preventing lower respiratory tract infection. 
Bronchoscopy is easily performed as a day-case procedure under sedation (2). The author’s experience is that 
older CF patients consistently report improvements in respiratory wellbeing irrespective of the indication for the 
procedure. Performed by highly experienced personnel in specialized centres, the risks are minimal. At present, 
it would be impractical to perform bronchoscopy on a 2-3month basis in all children who cannot be induced to 
expectorate sputum but an annual investigation as a minimum would be invaluable both in characterizing 
respiratory status and indicating the need for ongoing therapies. Given the provision of screening programmes to 
detect CF patients before the onset of irreversible lung complications, the author’s group believe that regular 
bronchoscopy is the single most important realizable advance in early management. More accurate identification 
of chronic infection between acute exacerbations of symptoms provides the opportunity to accurately target 
antibiotics and sensitively measure their effectiveness in reducing lung damage. 
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Lung surfactant in the lung 
T. POSTLE*, A. MANDER", K. REIDt, J.-Y. Wmxt, M. MOUSTALLI' AND J. WARNER" 
*Child Health, University of Southampton, Southampton, U.K. and TlMRC Immunochemistry Unit, 
Department of Biochemistry, Oxford University, Oxford, U. K, 
BACKGROUND 
Lung surfactant is a complex lipoprotein mixture, comprised predominantly of phospholipid and specific 
proteins, which is secreted from the type II alveolar epithelial cell and is distributed at the air-liquid interface 
throughout the lungs. The primary, well-recognized function of surfactant is to minimize the effects of surface 
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tension forces within the lungs, and so prevent alveolar collapse on expiration. Primary deficiency of lung 
surfactant is the principal cause of idiopathic respiratory distress syndrome (RDS) in preterm infants, while 
secondary inhibition of surfactant function contributes significantly to the pathogenesis and disease progression 
in adult RDS. In addition to these physical effects at the alveolar level, surfactant components exhibit many 
additional properties, and surfactant abnormalities have been proposed to contribute to the severity of lung 
disease in cystic fibrosis (CF). Surfactant can be demonstrated as an osmiophillic liming layer throughout the 
bronchial tree, and attention in CF has focused on the role of airway surfactant in promoting ciliary beat 
frequency (1). Consequently, impaired surface tension and rheological properties of bronchial mucus surfactant 
in CF have been suggested to contribute to the enhanced susceptibility to bacterial infection (2,3). 
Considerable evidence suggests that individual components of surfactant exert multiple direct immunomodu- 
latory properties. Interaction with airway surfactant is the initial event experienced by inhaled micro-organisms 
within the lungs. The considerable surface pressure of this airway surfactant has been proposed as a major force 
that acts to trap particles within the airways and to enhance their presentation to alveolar macrophages and 
airway dendritic cells. The hydrophilic surfactant proteins A and D (SP-A and SP-D) interact with bacterial and 
viral pathogens through lectin-mediated binding to carbohydrate recognition domains (45). typically promoting 
aggregation of the micro-organism and acting as opsonins, stimulating phagocytosis by alveolar macrophages 
(4). Importantly, in respect of the critical role of Pseudomonas colonization in the pathology of the CF lung, SP-D 
but not SP-A is reported to bind to Pseudomonas aeruginosa lipopolysaccharide (5). 
SP-A and SP-D are also directly involved in the regulation of inflammatory cell function within the lungs. 
Alveolar macrophage uptake of bacteria is enhanced by pre-incubation with SP-A (6), which also exhibits 
antioxidant effects (7) and is a chemotactic agent for alveolar macrophages (8). SP-D binds to alveolar 
macrophages by lectin-dependent mechanisms and is a potent neutrophil chemo-attractant (9). Many of these 
stimulatory effects of hydrophilic surfactant proteins on immune and inflammatory cells are regulated in the 
opposing direction by surfactant phospholipids. Surfactant phosphatidylcholine (PC) inhibits both neutrophil 
respiratory burst (10) and lymphocyte proliferation, while SP-A potentiates both responses (11). Consequently, 
the relative proportions of phospholipid and protein components of surfactant may contribute to the regulation 
of the host defence responses of lung inflammatory cells to bacterial infection. Previous studies of surfactant 
composition in CF have analysed phospholipids in sputum and bronchial secretions (12-15), but the extensive 
contribution of leukocyte membrane phospholipid to mucus and sputum in CF limits the value of these analyses 
as indicators of surfactant composition. Consequently, in this study, the authors have characterized surfactant 
phospholipid composition and SP-A and SP-D concentrations in bronchoscopy of children with CF and other 
respiratory conditions. 
METHODS 
Bronchoalveolar lavage fluid was collected from children undergoing fibre-optic bronchoscopy for diagnostic 
reasons. They included 13 children with CF, 11 other children with a variety of lung infections, and 11 children 
with structural abnormalities of the upper airways and no discernible infection who were regarded as a control 
group. The age range of the control group (6-84, median 13 months) was considerably lower than that of the 
infection (4-l 18, median 44 months) or CF (12-192, median 90 months) groups. BAL fluid was centrifuged at 
400 x g x 10 min for cytological examination, and surfactant components were analysed in the supernatant. 
Phospholipids were extracted with chloroform/methanol and analysed by direct injection electrospray ionization 
mass spectrometry (ESI-MS) (16). Molecular species of PC were determined under conditions of positive 
ionization, while those of phosphatidylglycerol (PG) and phosphatidylinositol (PI) were preferentially detected 
using negative ionization. Concentrations of SP-A and SP-D were measured by ELISA using polyclonal 
antibodies. Total phospholipid was measured as inorganic phosphorus. 
RESULTS 
The concentration of total BAL phospholipid in the CF group (333400, median 98 nmol ml- ‘) was only 
marginally but not significantly greater than that of the control (10-300, median 67 nmol ml- ‘) or infection 
groups (20-161, median 86 nmol ml-‘). This result is in direct contrast to previous phospholipid measure- 
ments on bronchial secretions, which reported significant elevations in CF. These previous studies also 
demonstrated decreased fractional contents of disaturated PC and PG, which are active components of 
surfactant, and increased contents of sphingomyelin and phosphatidylethanolamine, both characteristic of 
membrane phospholipid. 
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SP-A (ng nmol - ’ phospholipid) SP-D (ng nmol - ’ phospholipid) 
Range Median Range Median 
Control 30-587 319 0.19-33.1 5.52 
Infection 133460 150 0.00035-9.2 0.21 
Cystic fibrosis 0.54-l 16 23” 0.00024.97 0~0009** 
The availability of the ESI-MS technology enabled this discrepancy to be examined in more detail. ESI-MS 
is a novel technique of exquisite sensitivity, permitting complete quantification of surfactant phospholipids from 
as little as 1 ml of BAL fluid. ESI-MS analysis demonstrated negligible differences in the molecular species 
compositions of PC, PG or PI between the three groups of children. Similarly, the relative proportions of these 
three classes of phospholipids was unchanged. The mole percent concentration of dipalmitoyl PC (DPPC), the 
main surface active component of surfactant was 38.1 * 7.5% in the CF group compared with 36.2 f 10.3% in the 
infection and 41.8 3 3.3% in the control group. In contrast to the saturated nature of surfactant PC, BAL PG and 
PI was composed principally of mono-unsaturated and di-unsaturated species. This observation was significant 
as inflammatory cells contain negligible PG and polyunsaturated PI, showing clearly that the observations 
reported here related to surfactant and not inflammatory cell phospholipid. These results suggest strongly that 
there is no inherent abnormality of surfactant phospholipid in CF. In contrast to the surfactant phospholipid 
results, concentrations of SP-A and SP-D were both decreased in BAL fluid from CF children. SP-A 
concentration in the CF group (0.03-12.1, median 2.05 ,ug ml ~ ‘) was significantly lower (PcO.01) than in either 
the infection (1.8-24.6, median 9.8 pg ml- *) or control groups (5.4-24.3, median 12.4 pg ml - ‘). The decreased 
SP-D concentration in CF was even more dramatic, with values below the detection limits of the ELISA in eight 
of the CF group, in one of the infection group and in none of the control group. Median SP-D values for each 
group were respectively 0.05, 12.2 and 641 ng ml - I. To ensure that these low values for SP-A and SP-D in CF 
were not due to poor recovery of surfactant in those BAL samples, results were also expressed relative to total 
BAL phospholipid (Table 1). 
The decrease in SP-A:phospholipid ratio was confined largely to the CF group. SP-D:phospholipid was 
significantly decreased in the infection group, but there was a further considerable decrease in the CF group. The 
variation in the results for individual children within the CF group did not appear to be related to genotypic 
expression of mutant CFTR. SP-A and SP-D results were no different for the six subjects who were homozygous 
for AF508 compared with the remaining heterozygote children. There was, however, a non-significant suggestion 
that the nature of the bacterial lung colonization could affect SP-D but not SP-A concentrations. 
SP-D:phospholipid tended to be greater in children not colonized with Pseudomonas (0.00024.97, median 
0.118 ng nmol - ‘) compared to children colonized with Pseudomonas (0.0002-0.018, median 0.001 ng nmol - ‘). 
DISCUSSION 
In contrast to previous analyses of bronchial phospholipid compositions, this study has shown negligible 
alteration to the molecular compositions of PC, PG or PI in children with CF or other lung infections, when 
compared to children without lung infection. The conclusion that there is no fundamental abnormality to 
surfactant phospholipids in CF is in agreement with similar results from the CF mouse (17) and is perhaps not 
surprising given that alveolar collapse is not a common characteristic of lung disease in CF. By comparison, the 
lower amount of both hydrophillic surfactant proteins in CF is potentially important for the disease process. 
SP-A and SP-D are both part of the innate, non-specific host defence mechanisms against bacterial invasion of 
the lungs. Their decreased concentrations may contribute to the increased susceptibility to lung infection in CF, 
in particular as SP-D binds to Pseudomonas lipopolysaccharide. A central role for these proteins in lung host 
defence is supported by recent studies with the double negative SP-A mouse, which showed normal lung function 
in these animals (18), but an increased susceptibility to infection with both Staphylococcus aweus and 
Pseudomonas aevuginosa. The balance between surfactant phospholipid and protein may also be a significant 
factor in CF lung disease. While SP-A and SP-D are essentially pro-inflammatory, and will potentiate lymphocyte 
and neutrophil responses, surfactant phospholipid exerts predominantly anti-inflammatory effects. In the context 
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of CF, the presence of BAL fluid of normal phospholipid content but virtual absence of SP-A and SP-D may 
result in effective dampening of the neutrophil respiratory burst response in vivo, and consequently to impaired 
bacterial killing. It is intriguing that the only widespread trial of exogenous surfactant therapy in CF, which was 
largely ineffective, employed a protein-free preparation. In the light of these results, this may in effect have 
re-enforced an existing imbalance of surfactant composition in CF, and highlights the potential requirement to 
tailor the composition of therapeutic surfactants to the specific disease being treated. 
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The role of activated oxygen species in the pathogenesis of cystic fibrosis 
F. J. KELLY 
Lung Biology, Cardiovascular Research, The Rayne Institute, St. Thomas’ Hospital, London, U.K. 
INTRODUCTION 
Great advances have been made in understanding the underlying genetic defect in cystic fibrosis (CF). However, 
the cause of the severe lung damage that arises, and the subsequent pulmonary fibrosis that develops, remain 
unclear. The link between the CF gene, its biochemical consequences, and the increased susceptibility to 
pulmonary infection, particularly with Pseudomonas aeruginosa, remain to be elucidated. Although attempts have 
been made, it has proved extremely difficult to determine what constitutes a primary abnormality or what is a 
secondary consequence of infection. Irregularities in ion transport leading to inspissation of mucous secretions, 
along with increased adherence of bacteria to epithelia and reduced muco-ciliary clearance, are all thought to 
contribute to the recurrent, progressive, pulmonary infection characteristic of the disease. As successful 
genetic-based therapies may not be realized for some time, investigation of the physiological damage may prove 
more beneficial in the short term, to those already suffering from the disease. 
ACTIVATED OXYGEN SPECIES 
The role of activated oxygen species in a variety of diseases with pulmonary complications including hyperoxic 
lung injury in premature infants (l), adult respiratory distress syndrome (2,3), asthma (4) and the effect of 
environmental pollutants (.5,6) has recently attracted much attention. In all these conditions, oxygen free radicals, 
produced in a variety of ways, are thought to damage the pulmonary epithelium. Evidence is now accumulating 
that these reactive oxygen species may be important mediators of tissue damage in patients with CF (7-14), 
especially of the chronic lung injury. In recent years, reports of elevated concentrations of lipid (10,13), protein 
(10,13) and DNA (12) oxidation products in CF patients have appeared in the literature. 
When CF patients are considered as a group, evidence of oxidative stress is often present even in the presence 
of normal blood antioxidant concentrations. Importantly, however, antioxidant status decreases with age in CF. 
As it is often the older CF patients who have elevated oxidative stress, it is tempting to speculate that poor 
antioxidant status is responsible, in part, for their decline in lung function with advancing age. The reason for the 
fall in antioxidant status in CF is not clear; however, decreased compliance in taking vitamin supplements may 
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play a role. Alternatively, it is conceivable that repeated cycles of pulmonary inflammation, and associated 
oxidative stress, also contributes to the decline in antioxidant status. Whatever the exact cause, it is probable that 
the worsening antioxidant status of the CF adolescent contributes to their deteriorating clinical circumstances. 
POSSIBLE THERAPEUTIC STRATEGIES 
Interventions, which break the repeated cycles of oxidative stress, fall into two broad categories. Those which 
control the inflammatory response to infection and those which improve a patient’s ability to defend against the 
oxidative burden. The author’s group recently examined the first of these possibilities by recruiting patients who 
were about to receive intravenous antibiotic therapy for pulmonary infective exacerbations (15). Blood samples 
were taken prior to and following treatment (mean duration of 13 days) and a range of antioxidants, and markers 
of oxidative stress, were determined. A decrease in oxidative stress was observed as lower plasma cocnentrations 
of lipid hydroperoxides, post treatment. In addition, the plasma concentrations of vitamins C, A and E, increased 
27, 24 and 18%, respectively. These data support the theory that controlling the source of oxidative stress has 
beneficial effects in modulating the level of oxidative stress (and antioxidant status) in CF patients. Recently, 
Lepage et al. (16) reported that antioxidiant supplementation, the second possible therapeutic approach is also a 
potential means by which to control the extent of oxidative stress in FC patients. In particular, they demonstrated 
that p-carotene deficiency contributes to lipid peroxidation in CF, and that supplementation with the carotenoid 
leads to a significant reduction in circulating malondialdehyde levels. 
In summary, oxidative stress, arising from recurrent cycles of pulmonary inflammatory, plays a role in the 
deterioration of lung function in CF patients. Approaches which improve the innate antioxidant defences of 
the lung may prove to be useful adjuncts to steps that control recruitment of activated neutrophils to the lung, 
in the management of CF. 
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Nutrition and immunity 
D. J. SHALE 
University of Wales College of Medicine, U.K. 
The interaction between chronic pulmonary infection and inflammation, and nutritional status in cystic fibrosis 
(CF) is potentially a two-way process. There is little direct evidence of immune deficiency in CF, but differences 
in outcome are related to nutritional status and dietary intake. Such studies have been retrospective and 
cross-sectional in type, but indicate better preservation of pulmonary function and longer survival (1,2). There is 
supportive evidence from studies in malnutrition and chronic obstructive pulmonary disease that suggest the risk 
of infection is increased by poor nutrition. Therefore, the question remains does a poor nutritional status enhance 
pulmonary infection and inflammation in CF. 
It is likely that the interaction between immune mechanisms and nutritional status varies between children and 
adults. If there are effects of poor nutrition on immunity, they are likely to be fairly subtle and part of a 
multicomponent process. In either children or adults, once the lungs have become chronically infected, the 
immune response is likely to have a greater effect on nutrition and maintenance of body composition than visa 
versa. Weight loss is a feature of CF at many stages of the disorder, but is particularly prominent in adult patients 
with chronic infection and at the time of pulmonary exacerbations. The mechanisms of weight loss are 
multifactorial and may include poor nutrient intake, malabsorption secondary to uncorrected pancreatic 
insufficiency, excessive energy expenditure and catabolic intermediary metabolism secondary to pulmonary 
infection, and may co-exist in such patients and vary in their relative importance over time (3-7). The importance 
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of these considerations lies in the concept of energy imbalance. A negative balance leads to energy generation 
from host stores or from non-storage tissues in those with nutritional depletion. Studies in this area are difficult 
to conduct and attention has focussed on resting energy expenditure (RES), an index of basal metabolic rate, 
which is elevated in many patients with CF (3-13). Causes of this increase may include defect of CF (10-14) 
though the evidence is equivocal, the energy costs of breathing and the systemic effects of chronic pulmonary 
infection (6-13). The latter mechanism is likely to be particularly important in adults with continuous pulmonary 
infection. 
Increased RES has been related to the severity of lung disease (3,4) and the oxygen cost of breathing (OCB) 
accounts for up to 50% of the increased RES, though plasma tumour necrosis factor-a (TNF-a) concentrations 
account for a further 30% of the variation (7,15). Patients with chronic Pseudomonas aeruginosa infection have 
exacerbations of respiratory symptoms associated with increased circulating levels of C-reactive protein (CRP), 
neutrophil elastase-a, antiproteinase complex (NEAPC), interleukin-6 (IL-6) and TNF-w (16-18). Antibiotic 
treatment reduces the levels of these inflammatory mediators, but they increase when clinically stable suggesting 
that lung injury is continuous once infection is established (7,1618). Supporting the finding is the increased 
circulating concentrations of non-esterfied fatty acids (NEFA), glycerol and catecholamines that occur in 
clinically stable patients with chronic P. aeruginosa infection (7). This catabolic state is likely to be mediated by 
metabolically active products of the inflammmatory response or counter regulatory hormones. In 22 adult 
patients with CF and chronic P. aeruginosa infection, the relationship between REE and the inflammatory and 
metabolic responses was explored using antibiotic treatment to reduce the intensity of the inflammatory response. 
Patients were studied on days 1, 8 and 15 of a period of antibiotic treatment. REE was measured by indirect 
calorimetry and circulating concentrations of CRP, NEAPC, catecholamines and non-esterified fatty acids 
(NEEA) was determined. The mean (95% confidence interval) % predicted FEV, was 28.5 (20.6-36.4)O/ and mean 
body weight was 50.7 (47454.l)kg. Both FEV, and weight increased significantlyafter antibiotic treatment 
whilst circulating CRP (P<O.OOOl) and NEAPC (P<O.OOOl) were reduced. REE decreased from 6.8 (6.3-7.2) to 
6.3 (5.9-6.6) MJ day-’ by day 15 (P<O.OOOl). Weight gain was inversely related to REE (r=O.43, P=O.O2) and 
unrelated to energy intake (r=0.02, PyO.47). Post treatment reduction in norepinephrine was related to changes 
in REE (r = 0.5 1, P = 0.00 1) and NEFA (r < 0.05). There was no significant change in dietary intake, either in terms 
of total energy or the pattern of substrates. 
These parallel changes suggest co-regulation of the inflammatory and metabolic responses. Some of the 
reduction in REE may be due to a reduction in the OCB, but the related reduction in REE, catabolism and 
inflammation indicates a relevant physiological link between energy balance, weight control and chronic 
pulmonary infection. It is unlikely that altered pulmonary mechanisms caused such metabolic changes, which 
resemble many of the short-term catabolic adaptations in systemic sepsis or following infusion of endotoxin or 
TNFa. Thus, the link between pulmonary infection and nutritional depletion may be a non-adapting acute phase 
host response, rather than simple malnutrition which induces an energy conserving process with a reduction in 
REE, whilst the former is a catabolic and potentially host damaging process of more than short-term duration. 
The long-term implication of these interactions may be a vicious cycle of nutritional depletion and loss of 
respiratory function. 
This allows the development of a unifying hypothesis between chronic pulmonary infection and nutritional 
status CF, that the catabolic state is partly responsible for the problems of weight control, derangements of bone 
mineralization and the development of diabetes mellitus. Reduction in the intensity of the catabolic state in 
addition to good nutritional intake and control of pancreatic and gastro-intestinal issues, will produce beneficial 
changes in weight control, body composition, bone turnover and glucose tolerance. This hypothesis puts the host 
protective response to chronic pulmonary infection at the centre of the cause of the long-term complications and 
morbidity in CF, which are increasingly important in the management of the growing adult population. 
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Glucocorticoids alter ion transport in human nasal epithelium 
H. L. BOLTONt, P. RICHARDSONt, N. D. CARTER*, C. F. J. RAYNERS AND E. H. BAKER’ 
*Unit of Clinical Pharmacology, Department of Pharmacology, TDepartment of Physiology, 
$Medical Genetics Unit and S;Department of Respiratory Medicine, St George’s Hospital and Medical School, 
London, U.K. 
Hypersecretion and reduced clearance of abnormal mucus are features of many respiratory tract diseases. 
In cystic fibrosis, altered ion transport across the respiratory tract epithelium causes abnormal mucus and 
severe lung damage. Abnormal ion transport may also contribute to the development of more common airway 
diseases such as asthma and chronic bronchitis. Glucocorticoids may exert some of their therapeutic effect in 
these conditions by altering ion transport and mucus properties. The authors have examined the effect of 
glucocorticoids on airway ion transport using nasal potential difference measurements. 
Ten healthy male volunteers with no history of airways disease had nasal potential difference measurements 
before and after the local application of 10 - 4 M amiloride which blocks epithelial sodium channels. Recordings 
were repeated 4 and 24 h after the topical application of 2OOpg betamethasone 2 hourly and compared to the 
control values. 
Values given are the mean of five recordings made at different sites along the length of the inferior turbinate. 
The lumen was always negative compared to the submucosa. Baseline potential difference (PD) was 
- 17.5 f 26 mV (mean rf: SD) and did not change in response to betamethasone application (value after 
betamethasone: 4 h:16.7 * 5.5 mV; 24 h:17.1 & 6.5 mv). Amiloride reduced the PD by 6.7 + 4.5 mV in the 
untreated state (amiloride-sensitive PD). After betamethasone treatment the amiloride-sensitive PD had 
increased to 7.3 f 4.5 mV by 4 h (NS) and to 10.1 f 5.6 mV after 24 h (P=O.O058, paired t-test). 
Betamethasone, a selective glucocorticoid, increases amiloride-sensitive nasal PD which may reflect an increase 
in sodium transport through epithelial sodium channels. Glucocorticoids may be therapeutic in respiratory 
disease, not only through anti-inflammatory effects but also by altering the composition of airway secretions 
secondary to an increase in sodium reabsorption. 
Intravenous ouabain and hypertonic saline aerosol increase mucociliary clearance in the 
guinea pig 
B. B. NEWTON AND R. L. HALL 
Bayer Plc, Stoke Court, Stoke Poges, U.K. 
Reduced mucociliary clearance (MCC) and mucus accumulation are clinical features of cystic fibrosis (CF). 
Mechanisms behind the reduction in MCC remain incompletely understood; however, in vitro studies have shown 
that the transportability of mucus is governed in part by its ionic composition (Wills et al. J CZin Invest 1997; 99: 
9-13). The authors have investigated the effect of the selective NaC, K+-ATPase inhibitor ouabain (i.v.) and an 
inhaled aerosol of hypertonic saline in a guinea pig model of tracheal mucus velocity (TMV) (Read et al. J Appl 
Physiol 1992; 72: 2271-2277). These agents were administered in an attempt to explore a possible relationship 
between mucociliary clearance (MCC) and ionic composition of airway surface liquid (ASL). TMV was 
monitored using a collimated P-particle probe arranged to detect 32P-labelled Saccharomyces cerevisiae 
transported on the tracheal mucociliary layer of an anaesthetized guinea pig. Naive male guinea pigs were used. 
Ouabain (10 or 30 pug kg - ‘) or saline (0.9%) was administered intravenously and TMV (mm min - ‘) was 
measured after 5, 20, 35, 50 and 65 min. A significant increase in TMV was observed at 35 min after 3Oyg kg - ’ 
ouabain. TMV was 5.1 f 1.2 (n=7) in saline-injected animals compared to 7.8 * 2.3 (n= 8) in animals injected 
with 30 ,ug kg - ’ ouabain (PI 0.05; median f semi-interquartile range; Mann-Whitney U-test). In a second 
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study, a 5-min aerosol of hypertonic saline (14.4%) or saline (0.9%) was administered. TMV was monitored at 1, 
15 and 30 min following termination of the aerosol. A significant increase in TMV was only observed 1 min after 
hypertonic saline aerosol. TMV was 5.1 & 1.0 (n=9) in 0.9% saline-exposed animals compared to 11.3 =t 1.3 (n= 9; 
P < 0.001) in hypertonic saline-exposed animals. These data indicate that agents and procedures that modify ion 
movement and ion concentrations in the airway epithelium also influence MCC in normal animals. 
Bronchoalveolar lavage fluid antioxidant status in bronchiolitis obliterans syndrome: a 
preliminary study 
A. WILLIAMS”, G. RIIsEt AND F. J. KELLY* 
“Cardiovascular Research, The Rayne Institute, St Thomas’ Hospital, London, U.K., and TDepartment of 
Pulmonary Medicine, Suhlgrenska University Hospital, Giiteborg, Sweden 
Long-term survival following lung transplantation is limited by the onset of chronic rejection in the form of 
bronchiolitis obliterans syndrome (BOS). BOS is associated with infiltration of activated neutrophils into the 
lung. As these could modulate lung antioxidant status, the authors assessed bronchoalveolar lavage (BAL) fluid 
antioxidants in lung transplant recipients with and without BOS. BOS was diagnosed clinically and histopatho- 
logically by transbronchial biopsy (TBB). Twenty-six lung transplant recipients were recruited into the study, 13 
with BOS [age 46 (44.52) years, 9 female/4 male] and 13 post-transplant controls without BOS [age 45 (29, 51) 
years, 9 female/4 male]. A single BAL followed by TBB was performed on the subjects (groups were time 
matched). BAL fluid concentrations of the water-soluble antioxidants, ascorbate, urate and reduced glutathione 
(GSH) were determined, as well as the oxidative stress marker oxidized glutathione (GSSG) and protein 
(indicator of microvascular permeability). Data shown as medians (25th, 
pmoll-’ 
75th percentile) and expressed as 
with the exception of protein which is mg ml - ‘. Statistics were performed using Mann-Whitney U-test 
and Spearman Rank Correlation for non-parametric data. Although considerable variability was observed, BAL 
fluid antioxidant status (ascorbate, urate, GSH) was lower in patients with BOS. Moreover, these transplant 
recipients also had high levels of GSSG and protein in their airways. Myeloperoxidase (neutrophil activation 
marker) correlated positively with protein (r=O.33, P=O.O48), and the % neutrophils in BAL fluid were correlated 
negatively with GSH concentration (r= - 0.37, P=O.O31). Combined, these findings indicate that oxidative stress 
may play a role in BOS development. Further examination of this question in a larger cohort of patients is 
warranted. 
Parameter Controls BOS 
Ascorbate 0.56 (0.31, 0.79) 0.31 (0.27, 0.49) 
Urate 3.04 (2.43, 3.69) 2.64 (1.86, 3.08) 
GSH 2.26 (1.28, 3.00) 1.17 (0.72, 1.76) 
GSSG 0.001 (0.001, 1.31) 0.10 (0.02, 2.31) 
Protein 0.28 (0.22, 0.37) 0.42 (0.20, 0.64) 
Comparison of coughed, expectorated and induced sputum samples from cystic fibrosis 
patients obtained during a course of intravenous antibiotic therapy 
K. DUNBAR, J. HOWARD, C. PATTERSON, L. MARTIN AND S. ELBORN 
Northern Ireland Adult Regional Cystic Fibrosis Centre, Department of Respiratory Medicine, 
Belfast City Hospital, Belfast, Northern Ireland, U.K. 
An optimal method of sputum collection from cystic fibrosis (CF) patients has not yet been established. The 
collection method used should yield sufficient volume of supernatant to permit measurement of biochemical and 
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inflammatory parameters such as neutrophil elastase activity (NEA). The aim of this study was to compare three 
different collection methods from six CF patients at the beginning and end of a 2-week course of intravenous (i.v.) 
antibiotic therapy. A single cough sample (CS), an expectorated sample obtained during a 30-min physiotherapy 
session (ES) and an induced sample obtained by inhalation of a 3% hypertonic saline solution via an ultrasonic 
nebulizer (IS), were collected from each patient on days 1 and 12 of the antibiotic therapy. The samples were 
collected in sterile containers and processed within 30 min. The sputum was centrifuged for 1 h at 30 000 g, at 
4°C. The supernatant was aspirated and the volume recorded. The sputum sol was then aliquoted into smaller 
volumes and stored at - 70°C until assayed. 
NEA was measured using a chromogenic assay (substrate - Succinyl-Ala-Ala-Pro-Val-p-nitroanilide) and 
expressed as total NEA &g) for each sample. NEA was demonstrated in all samples; however, a significant 
reduction in this parameter was observed at the end of antibiotic therapy as compared to day 1 (P=O.OOl). This 
difference was most clearly observed using IS (day 1 mean= 12964 pg, day 12 mean=2543 pg, P= 00.03). There 
was a significant difference in total NEA between CS (mean= 15.35 pg) and ES (mean= 13.84pg, P=O.O13), and 
between CS and IS (mean=99 56,ug, PzO.019). However, no significant difference was observed in total NE 
found in ES and IS samples (PzO.013). All the collection methods provided sol which could be used to follow 
changes in NEA which may reflect alteration in airway inflammation events during a course of antibiotic therapy. 
The IS method, however, yielded the largest volume of sol (mean= 5.05 ml) which was significantly greater than 
both ES (mean= 1.4 ml, P=O.O004) and CS (mean=0.49 ml, P=O,O16). IS: therefore, provides sufficient sol to 
facilitate extensive biochemical analysis to determine the extent of lung inflammation and injury. As this is an 
ongoing study, patient numbers will be enlarged to further clarify these findings. 
Spoken Presentations 
Migration of neutrophils through human pulmonary endothelial monolayers is not 
inhibited by inhibitors of matrix metalloproteinases 
A. J. MACKAREL, K. J. RUSSELL, K. J. MCMAHON, D. C. COTTELL*, M. X. FITZGERALD AND 
C. M. O’CONNOR 
Department of Medicine and *Electron Microscopy Unit, University College Dublin, Beljield, Dublin 4, Ireland 
During inflammation, neutrophils migrate through the endothelium of the blood vessel wall. Matrix metallopro- 
teinases (MMPs), in particular gelatinase B, have been implicated to have a role in this process by digesting the 
subendothelial basement membrane. The aim of this study was to examine the involvement of MMPs in 
transendothelial neutrophil migration. Human pulmonary artery endothelial cells (HPAEC) were grown on 
microporous membrane filter inserts coated with human type IV collagen. After 4 days, scanning electron 
microscopy demonstrated that HPAEC formed a continuous layer covering the entire filter surface. Transmission 
electron microscopy of transverse sections of these HPAEC cultures revealed the presence of a bilayer of 
endothelial cells, a monolayer with complete subendothelial basal lamina on each side of the filter. Migration 
of neutrophils (isolated from human venous blood) across the HPAEC bilayer in response to 
n-formylmethionylleucylphenylalanine (FMLP) was assessed following a 3 h incubation at 37°C. Although 
42.1 ZIZ 4.1% (mean & SEM, n=6) of neutrophils adhered to HPAEC in the absence of FMLP, transendothelial 
migration was minimal. In response to 10 - ’ M FMLP, 61.5 f 5.7% (mean+ SEM, n=6) of added PMNs 
migrated through the bilayer. Although FMLP-stimulated PMNs released I.&fold more gelatinase B, the 
presence of the MMP inhibitors, TIMP-1 (10 - 7M) and GM6001 (10 - 6M), did not inhibit transendothelial PMN 
migration. In vivo, the blood-air barrier of the alveoli consists of endothelial- and flat, plate-like Type 1 epithelial 
cells lining either side of a fused basement membrane. The HPAEC bilaver model described here, by providing 
two distinct cell barriers separated by basal lamina, is an in vitro approximate of the blood-air barrier. Inhibitors 
of MMPs did not inhibit PMN migration across the HPAEC bilayer system. Results of this study suggest that 
MMPs are not involved in the process by which PMNs traverse the blood-air barrier during pulmonary 
inflammation. (This work was funded by Health Research Board, Ireland.) 
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a,-Antitrypsin mutations and cystic fibrosis lung disease 
R. MAHADEVA*,t, S. STEWART+, D. BILTONt AND D. A. LOMAS” 
“Departments of Medicine and Haematology, University of Cambridge, MRC Centre, -fCF Centre and 
$Department of Pathology, Papworth Hospital, Cambridge, U.K. 
An imbalance between proteinases such as neutrophil elastase and their inhibitors, most notably a,-antitrypsin 
(q-AT), is thought to be an important factor in the progression of cystic fibrosis (CF) lung disease. The authors 
have recently shown that 20/150 unrelated patients who had mild to moderate antitrypsin deficiency (16 MS, 1 SS 
and 3 MZ) did not have more severe lung disease but unexpectedly had significantly less severe lung disease as 
assessed by FEV,%; (adjusted means 62.5% for those with a deficient phenotype and 51.1% for the normal group; 
P= 0.043). As most of the index population in the authors’ initial investigation were adults, it is possible that the 
most severely affected patients would have died and have been excluded from the study. The authors have now 
undertaken a further investigation of a,-antitrypsin deficiency alleles in the most severely affected patients, i.e. CF 
children who have died and adults who have been transplanted for CF lung disease. Blood spots were available 
on six children who had died of pulmonary disease, and formalin-fixed lung tissue was available on 67 CF 
patients who had undergone heart-lung transplantation at Papworth Hospital. The presence or absence of the 
common S and Z deficiency alleles was determined by the polymerase chain reaction and restriction enzyme 
digestion of isolated genomic DNA. The author’s data show that one of 73 patients (1.4%) were heterozygous for 
the Z allele and two patients (2.7%) were heterozygous for the S allele of antitrypsin. No Za,-antitrypsin 
homozygotes were detected. These values compare with an incidence of 8 and 3% for the S and the Z alleles, 
respectively, in the U.K. population. This data supports the authors’ previous observations that mild to moderate 
deficiency of antitrypsin is not associated with more severe lung disease in CF, and may be associated with an 
improved outlook from the condition. 
Improved antioxidant status of cystic fibrosis patients following antibiotic treatment 
C. A. DUNSTER”, S. P. RANGEt, A. J. KNOXt AND F. J. KELLY” 
“Lung Biology, Cardiovascular Research, The Ruyne Institute, St Thomas’ Hospital, London, and ?-Division of 
Respiratory Medicine, City Hospital, Nottingham, U.K. 
The prevalence of oxidative products in plasma from cystic fibrosis patients has been reported previously (Brown 
& Kelly Pediatr Res 1994 36: l-7). The authors hypothesized that if the oxidative burden, arising from activated 
neutrophils and macrophages in the lung, was decreased by treatment of pulmonary infection, then fewer 
oxidative products would be observed. This response, in turn, should have a favourable effect on the antioxidant 
status of the patient. To examine this hypothesis, 17 patients (10 females/7 males, mean age 26 f 5 yr) receiving 
intravenous antibiotic therapy for pulmonary infective exacerbations were studied. Blood samples were taken 
prior to and following treatment (mean duration of 13 & 3 days) and a range of antioxidants was determined. 
Pre-treatment Post-treatment 
FEV, (1) 1.21 ( & 0.54) 1.47 ( * 0.73)” 
Vitamin C 01W 29.9 ( xt 18.6) 41.2 (* 28.9)” 
Urate WW 322.7 ( 41 109.4) 251.1 (zt 91.7)” 
Vitamine E Cu W 19.9 (& 11.3) 24.1 (* 11.5)” 
Vitamine A Cu W 1.9 ( + 0.7) 2.5 (f 1.3)” 
The data, presented as means ( & SD), were analysed by paired t-test. *denotes a difference (PcO.05) from the 
pre-treatment value. FEV, improved significantly post-treatment, indicating better lung function probably due to 
decreased pulmonary infection. The latter would result in a decrease in oxidative stress and this was evident as 
lower plasma concentrations of lipid hydroperoxides; 10 (10, 15.3) W. 14 (10, 44.3)nM post-treatment. In 
addition, the concentration of the water-soluble antioxidant, vitamin C, increased 27%, and the lipid-soluble 
ABSTRACTS A. 7.5 
antioxidants, vitamin A and vitamin E, increased 24 and 18% respectively. Only the concentration of uric acid 
fell post-treatment (22%). It is concluded that treatment with antibiotics not only improves pulmonary function 
but also results in decreased oxidative stress and improved antioxidant status. 
Ozone-exposed respiratory tract lining fluid-mediated toxicity in lung macrophages and 
epithelial type II cells 
I. S. MUDWAY”, T. D. TETLEYt, K. CHARALAMBOUSt, I. R. WITHERDENt AND F. J. KELLY* 
*Cardiovascular Research, The Rayne Institute, St Thomas’ Hospital and t Cardiopulmonary Medicine, 
Charing Cross & Westminster Medical School, London, U.K. 
Ozone (0,) uptake into the lung is coupled to its reaction with substrates present at the air/liquid interface, the 
respiratory tract lining fluid (RTLF). These reactions are considered protective where they are with antioxidants, 
or harmful, with protein and/or lipid moieties. The authors investigated the role of RTLF antioxidants in 
modulating the formation of these toxic species by assessing cellular responses following incubation of rat type 
II (TII) cells or macrophages (MC) with autologous bronchalveolar lavage fluid (BALF) that had been exposed 
to 0,. 
Excised rat lungs (200 g, male Wistar) were lavaged (6 x 8 ml Ca2+/Mg2+ free HBSS, pH 7.4), TII cells isolated 
and cultured (Richards et al. Lung 165: 143-158). Lavage fluid was centrifuged (400 g for 15 min, 4°C) and the 
acellular supernatant stored at - 80°C until required. The cell pellet (MC) was resuspended in serum free media, 
plated out at lo6 cells ml - ’ and MC selected by adherence. Thawed, autologous BALF was exposed to 0, 
(1000 ppb) and air, as separate 1 ml aliquots, using a novel, mixed, interfacial exposure system (Mudway et al. 
Free Red Res 25: 499-513). After 0, 5, 15, 30, 45 and 60 min exposure BALF was removed and immediately 
placed onto confluent TII cells (4 days) and MC (24 h) for 2 h at 37°C. These cells had been pre-labelled with Cr51 
and washed with HBSS. Cellular integrity was assessed by Cr” retention, acid (MC)/alkaline (TII cells) 
phosphatase, glutathione S-transferase (GST) and y-glutamyl transpeptidase (GGTP) activities. 
Two hour incubation with BALF pre-exposed to 0, for 5 min resulted in significant (P<O.Ol) loss of Cr5’ and 
acid phosphatase activity from MC. Relative to control (native BALF), Cr5’ in the cell mat fell by - 19.6 (2.6)% 
{0,} vs - 1.9 (l.O)% {air], and acid phosphatase - 14.6 (2.6)% CO,} vs 2.2 (6.9)% {air}, n=6. Maximal loss of 
Cr51 was observed following incubation with BALF exposed to 0, for 15 min - 42.2 (3.2)%; this did not change 
with longer pre-exposure of BALF to 0,. In contrast, reduction in acid phosphatase was related to time of 
pre-exposure of RTLF to O,, being maximal after 60 min O,, at - 43.3 (1.9)%. GST tended to go down, while 
GGTP tended to increase with length of BALF 0, pre-exposure. Antioxidant supplementation (100~moll~ ’ 
ascorbate/urate) of BALF prior to 0, exposure resulted in a complete loss of MC toxicity, suggesting prevention 
of toxic species formation. In contrast, TII cells showed no loss of cell integrity or function after 2 h incubation 
with any of the pre-exposed BALF samples. However, if the incubation period was increased to 4 h, then 
significant losses of Cr51, alkaline phosphatase and GST activities, and an increase in GGT occurred (BALF 
pre-exposed to 0, for 15 min). TII cell sensitivity to O,-exposed BALF could be induced earlier (2 h) by the 
depletion of BALF ascorbate and urate prior to 0, exposure, using ascorbate oxidase and uricase. 
Exposure of RTLF constituents to 0, results in the formation of cytotoxic species after short exposure periods. 
Formation of these toxic species is critically related to the antioxidant status of the RTLF. MC are more sensitive 
to these toxic species than TII cells, which implicates the MC as an early modulator of r&-induced toxic effects 
in the lung. 
Total antioxidant capacity in children with cystic fibrosis 
S. B. CARR”, J. FemRt, I. MERRYWEATHER*, R. Duvwmm AND D. MULLER+ 
*Royal Free Hospital, TGreat Ormond Street Hospital and IInstitute of Child Health, London, U.K. 
It has been established that there is an antioxidant imbalance in children with cystic fibrosis (CF) with the 
suggestion that there is increased oxidative stress and decreased antioxidant capacity (Brown & Kelly Thorax 
1994; 49: 738-742). This study has examined whether CF children with severe lung disease, FEV, ~45% (forced 
expiratory volume in 1 s) have a poorer total antioxidant capacity than those with mild lung disease, FEV, >70%. 
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A group of 10 children with FEV, ~4.5% were compared to a similar group with FEV, >70%. The total 
antioxidant capacity of plasma was measured using the Randox total antioxidant assay. Vitamin E, C-reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR) were estimated as well as height, weight and dietary 
intake data. Analysis was by independent t-tests, Results are expressed as the FEV, ~45% group vs. the FEV, 
>70% group, mean (SE). There were no significant differences between any of the parameters investigated. The 
ages of the two groups 13.6 (0.9) v,s. 12.8 (0.6) years, total antioxidant capacity 1.39 (0.05) vs. 1.39 (0.03) mmol 
1-l. Vitamin E: 12.2 (2) vs. 17.2 (2.2)pmol l- ‘, vitamin A 244 (35) vs. 289 (38) p gl- ‘, CRP 1.2 (0.3) V.Y. 1 
(0.2) mg dl- ‘, ESR 39 (8) vs. 24 (6) mm h- ‘. The energy intake expressed as % estimated average requirements 
was also the same in the two groups, 116% (7.7) vs. 112% (17). In conclusion, this study does not show any 
difference in the capacity for antioxidant defence between children with severe lung disease and those with mild. 
This would suggest that the increased risk of oxidative damage in the severe group, as a result of increased 
inflammation and infection, has not had an adverse affect on antioxidant status. There was also no evidence for 
different intakes of the dietary antioxidants between the two groups. Whether the total antioxidant capacity is 
sufficient (normal population range 1.30-1.77 mmol I- ‘) to counter the increased demands in CF still needs to 
be addressed. 
Successful treatment of Mycobacferium cheloncre with immunotherapy using 
mycobacterium vaccae vaccine 
A. L. DEWARAND G.J. CONNETT 
Department of Paediatrics, Southampton University Hospitals Trust, Southampton, U.K. 
Atypical mycobacteria are recognized pathogens of the lower respiratory tract in cystic fibrosis. The emergence 
of multi-resistant strains is a recognized phenomenon limiting the effectiveness of antibiotics. The authors report 
a 15-year-old boy successfully treated by immunotherapy, having failed to respond to intensive antibiotic 
treatment. He was diagnosed aged 2 months and is heterozygous for the AF508 and G551D mutations. 
Continuous neublized antibiotics were commenced at the age of 6 years following isolation of Pseudomonas 
aeruginosa. Lung function was normal and weight for height 100% until aged 13 years. Lung function 
subsequently declined and weight was static. Repeated sputum cultures were positive for acid fast bacilli and 
cultured pan-resistant Mycobacterium chelonae. Lung function declined despite treatment with oral Azithromycin 
plus Co-trimoxazole (1 month), oral Ciprofloxacin plus Clarithromycin (2.5 months) and i.v. Cefoxitin plus 
Amikacin (2 months) to an FEV, of 41% predicted. Over the next 8 months, he received four doses of intradermal 
Mycobacterium vaccae. Within 2 months, FEV, and FVC increased to 80 and 100% of predicted, respectively, 
and have remained at these levels. Previous anorexia improved and weight has increased. Serial T-cell subset, 
analyses during treatment showed a decline in IL-4 producing cells and increases in those producing y interferon. 
He has remained Gram-stain and culture positive. M vaccae is a powerful Thl adjuvant. Results suggest it might 
be of value in treating mycobactreia infection by switching host immunity from Th2 to Thl responses. 
Anti-inflammatory therapy for lung disease in cystic fibrosis: current paediatric practice 
in U.K. 
I.M.BALFOUR-LYNN* AND C.D~z~-r~uxt 
“Respiratory Unit, Great Ormond Street Hospital for Children and 7 Unit of Epidemiology & Biostatistics, 
Institute of Child Health, London, U.K. 
It has been suggested that anti-inflammatory therapy may be an effective treatment for cystic fibrosis (CF) lung 
disease, but further evidence is required. While a recent survey revealed 34% of CF adults were taking inhaled 
corticosteroids (ICS) [Walters S. ASSO? of CF Adults (UK) Survey 1994. Published by CF Trust 19951, similar 
data for children are lacking. This national survey of U.K. CF centres was undertaken to determine the current 
use of ICS as well as ibuprofen in paediatric CF lung disease. 
Postal survey to the Paediatric Departments of all CF centres (n = 3 1) with over 50 patients (list provided by the 
CF Trust) was undertaken. 
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Replies were received from 30/31 (97%) centres treating almost 3500 patients under 18 years. In 70% of centres, 
patients took regular oral steroids, and overall they were prescribed for 5% patients. Usage was generally low with 
median (range) 4% (l-23%) patients, but five centres had over 10% patients on oral steroids. The main 
indications were ABPA and asthma/wheezing; however, four centres (13%) usually gave them for severe lung 
disease whilst 13 (43%) sometimes did. All centres had patients on regular inhaled steroids and overall they were 
prescribed for over 40% patients. Within the centres, usage was common (median 44%) although there was a 
wide range (lo-90%). Most centres (87%) usually gave them for troublesome wheezing; seven centres (23%) also 
usually gave them as anti-inflammatory therapy whilst 13 (43%) sometimes did. The practice of prescribing for 
lung inflammation started in the late 1980s and early 1990s in most centres. Only seven (23%) centres had even 
prescribed ibuprofen for lung disease and five of these had only given it to a single patient. 
The practice of treating CF lung inflammation in the U.K. varies widely between centres. ICS are used most 
frequently, with oral steroids reserved mainly for ABPA. The use of ibuprofen for lung disease is not routine in 
the U.K. Randomized trials are needed to clarify the exact roles of these potent drugs in CF as they are not 
without adverse effects, and in the case of ICS their widespread use will soon preclude such studies. 
Posters 
A dicistronic construct to detect the expression of human CFTR from YAC DNA in a 
human epithelial cell line 
G. VASSAUX AND C. HUXLEY 
Imperial College School of Medicine at St. Mary’s, London, U.K. 
Transgenic mice made with heterologous promoters driving the CFTR cDNA and even a recent knock-in mouse 
with the human CFTR cDNA inserted into the mouse gene have not fully complemented null CF mice, indicating 
that splicing and long-range controlling elements are probably necessary for full levels of tissue-specific 
expression. Towards characterization of the elements necessary for full levels of CFTR expression, the authors 
have described (Manson et al. EMBO J 1997; in press) transgenic mice carrying a 320-kb YAC with the intact 
human cystic fibrosis transmembrane regulator (CFTR) gene. In mice that only express the human transgene, the 
chloride secretory responses are as large or larger than in wild-type tissues, and expression of the transgene is 
highly cell-type specific and matches that of the endogenous mouse gene in the crypt epithelia throughout the gut 
and in salivary gland tissue. 
To further characterize the long range control of expression of the CFTR gene, the authors are making 
deletions of the YAC. However, it is very difficult to detect tissue-specific CFTR mRNA expression in transgenic 
mice except by 35S in situ hybridization. 
In order to be able to easily detect the tissue specificity of transgene expression, the authors have made a 
dicistronic construct where the picornaviral internal ribosome-entry site (IRES) driving expression of the P-geo 
gene has been inserted in the 3’ untranslated region of the human CFTR gene present in the YAC. When 
introduced into the human colonic adenocarcinoma cell line, Caco-2, which expresses the CFTR gene, the 
expression of the dicistronic gene can be detected by IacZ staining in a way which follows the accumulation of the 
CFTR mRNA upon differentiation of the Caco-2 cells. These data demonstrate that this IRES-based approach 
represents an alternative to mRNA in situ hybridization, and the authors now aim to use this construct in 
transgenic mice. 
Effect of nitric oxide on superoxide-mediated killing of Burkholdevia cepacia from cystic 
fibrosis patients 
C. EDEN, E. L. MILLS, J. GREEN, M. L. WATSON AND A. W. SMITH 
School of Pharmacy and Pharmacology, University of Bath, Bath, U.K. 
The primary defence in the lung against invading bacteria is effected by neutrophil and epithelial cell responses. 
The accumulation of large numbers of activated neutrophils in the lungs of cystic fibrosis (CF) patients provides 
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a major source of superoxide anion. There is also evidence of significant nitric oxide (NO) production in the CF 
lung, suggesting that bacteria may be exposed to the combined effects of reactive oxygen and nitrogen species. 
In this work, the authors have examined the sensitivities of the ‘epidemic’ B. cepaciu isolate 52315 and a 
non-clinical isolate (52552) to oxidant and NO-mediated killing. Although their abilities to elicit a neutrophil 
respiratory burst were similar, 52315 was significantly more resistant to superoxide anion, generated from the 
xanthine oxidase (100 mU ml- ‘)/hypoxanthine (10 mM) reaction, or 5 mM H,O,, than J2552. NO alone, 
produced from the spontaneous breakdown of sodium nitroprusside (50 mM) or S-nitroso-N-acetylpenicillamine 
(5 mM), was not toxic; however, combination with superoxide or H,O, resulted in inactivation of the oxidant 
resistant 52315. The superoxide/NO inactivation was not inhibited by superoxide dismutase (5000 U ml - ‘), 
whereas both superoxide/NO and H,O,/NO were inhibited by catalase. These data suggest that the toxic 
species may not be peroxynitrite, formed by the reaction of NO and superoxide, but rather species formed 
between NO and H,O,. The authors are currently examining the role of redox active iron in defence against these 
species. 
Excessive cyclic AMP rise is not required to correct defective CFTR-mediated mucin 
secretion 
M. A. MCPHERSON, M. M. C. PEREIRA, C. LLOYD MILLS AND R. L. DORMER 
Department of Medical Biochemistry, University of Wales College of Medicine, Card@ U.K. 
CFTR not only acts as a chloride channel, but is also a key regulator of mucin secretion (McPherson & Dormer 
Lancet 1994; 343: 7). The defect in CFTR-mediated P-adrenergic stimulation of mucin secretion is corrected by 
3-isobutyl-1-methylxanthine (IBMX). (McPherson & Dormer Br Med Bull 1992; 48: 766-784). 
The aim of the present study is to investigate the actions of adenosine A, and A, receptor antagonists to 
determine the mechanism of correction of defective CFTR function and whether excessive cyclic AMP rise is 
required. 
CFTR antibodies introduced into living rat submandibular acinar cells by hypotonic swelling induced the same 
phenotype as that seem in native CF submandibular cells, including correction by IBMX. The adenosine A, 
receptor antagonist, S-cyclopentyltheophylline (CPT) at 1 mM corrected CFTR antibody inhibited mucin 
secretion response (isoproterenol:IP alone 146.9 * 9.4; IP+CPT; 210.6 f 11.4, % basal, n=4; P<O.O5), whereas 
the A, receptor antagonist, dimethylpropargylxanthine (DMPX) was ineffective (IP alone: 155.0 + 14.5; 
IP+DMPX: 167.8 + 7.4, n=4). The cyclic AMP rise in response to isoproterenol was potentiated by IBMX 
(336 f 34%) and by DMPX (157 f 12%); however, CPT did not give any increase above that induced by 
isoproterenol alone (90 * 19%, n=6). The results show that the CFTR mucin secretion defect can be corrected 
without excessive increase in cyclic AMP. This affords promise for the development of a selective drug treatment 
for CF, aimed at correcting the basic defect. Supported by the Welsh Scheme and the CF Trust. 
Impact of impaired lean body mass on respiratory muscle function 
A. A. IONESCU, K. CHATHAM, C. DAVIES, L. S. NIXON AND D. J. SHALE 
Section of Respiratory Medicine, University of Wales College of Medicine, Llandough Hospital, Penarth, 
South Glamorgan, U.K. 
To assess the role of lean body mass (LBM) on inspiratory muscle function, 25 patients (10 female) with proven 
cystic fibrosis (CF) were studied; mean age (SD)=22.9 (3.8) years. All were clinically stable. The mean FEV,% 
predicted was 61.1%, range l&113%. Mean body mass index (BMI) (SD)=21.3 (3.8) kg rnp2. Body composition 
was assessed by four site skinfold measurement. Arm muscle circumference (AMC) was measured. Hand grip 
(HG) was measured as an indicator of skeletal muscle force. Inspiratory muscle force was assessed as maximum 
inspiratory pressure (MIP) and sustained maximum inspiratory pressure (SMIP). Serum CRP was measured to 
assess pulmonary inflammation. Patients with a low LBM (~67% ideal body weight) were compared with those 
with a normal LBM. The low LBM group had a lower FEV, (PzO.07). No difference in LBM was found between 
patients with normal and low FEV, (~70%). All parameters of inspiratory and arm muscle force were lower in 
patients with a low LBM compared with those with a normal LBM; SMIP P=O.OOl, MIP P=O.Ol, P=O.Ol 
(Table). An AMC ~70% of predicted was associated with a reduction in SMIP P<O.Ol, MIP PcO.05, HG 
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PcO.05 compared with an AMC >70% predicted. LBM and AMC were related r=0.45, P= ~0.05. Patients with 
a FEV, ~70% predicted had a lower SMIP (P=O.O3) compared with patients with a normal FEV,; MIP was not 
related to FEV, (P=O.l). 
In conclusion, nutritional (LBM) and functional (FEV,) status influenced skeletal muscle function, including 
inspiratory muscles. Patients with a low LBM have evidence of greater inflammatory activity, which suggests the 
association between continuing lung inflammation and metabolic changes that control nutrition. 
Mean (SD) MIP cm H,O 
SMIP (pressure 
time units) HG (cm H,O) FEV, % pred CRPpg ml-’ 
Group 1 72 (10) 247 (114) 22 (5) 40 (20) 18 325 (12 291) 
Group 2 106 (31) 554 (183) 37 (10) 69 (24) 2021 (1438) 
Quantitative ultrastructural immunocytochemistry of cytochrome P-450 in injured lungs 
R. GILBERT AND D. DINSDALE 
MRC Toxicology Unit, Leicester, U.K. 
Many pneumotoxins requiring metabolic activation cause selective injury to non-ciliated bronchiolar (Clara) cells 
but other compounds, which are activated by cytochrome P-450 2Bl {CYP2Bl), injure only the alveolar type I 
cell. This enzyme is present in both type I and Clara cells (Lee & Dinsdale Biochem Phavmacol 1995; 49: 
1387-1394) but the latter are apparently resistant to these compounds, even at doses which cause severe alveolar 
injury. 
Ultrastructural immunocytochemistry enabled the CYP2Bl protein to be localized within the cells of the 
normal rat lung, and these results were compared with those from samples taken 24 and 72 h after the 
administration of 50 mg kg- ’ O,O,S-trimethylphosphorothioate. This treatment resulted in the destruction of 
most type I pneumocytes. Detailed examination of the Clara cells indicated that most of their characteristic 
cytoplasmic granules were lost from the cells of dosed animals but no signs of injury were detected. Quantitation 
of the immunogold label was not possible in the lysed type I cells but an unexpected reduction was found in the 
cytoplasmic CYP2B 1 immunolabelling of Clara cells. The intensity of labelling, 24 h after dosing, was reduced to 
29% of that observed in the control animals and, by 72 h, it had fallen to 17%. These results confirm the 
particular susceptibility of type I cells to this toxin. They also indicate that the phase 2 enzymes of Clara cells are 
capable of preventing similar injury in these cells, but they are unable to prevent the destruction of the activating 
enzyme, probably by electrophilic metabolities. 
Phosphatidylcholine (PC) molecular species composition in cystic fibrosis (CF) 
newtrophils 
M. PETROVIC, A. MANDER, S. WRIGHT, E. HEELEY, J. WARNER AND T. POSTLE 
Child Health, University of Southampton, Southampton, U.K. 
The increased susceptibility to bacterial colonization in CF may be partly due to impaired host-defence responses, 
including neutrophil superoxide production and phagocytosis. Signalling for both responses involves hydrolysis 
of PC by phospholipase D to generate phosphatidic acid (PA). Alteration to neutrophil membrane PC 
composition in CF may generate PA species with different signalling properties, resulting in changed functional 
responses. Heparinized blood samples were taken from adults with CF (n = 1 I), bronchiectasis (n = 3) and control 
volunteers (n= 14). Phagocytic and oxidative burst responses to S. aureus were determined in whole blood by flow 
cytometry. Purified neutrophils were incubated * 100 nM phorbol ester (PMA) for 30 min, extracted with 
organic solvent, and their PC molecular species composition determined by electrospray mass spectrometry 
(EMS). EMS quantified over 30 PC species from 2.5 x lo6 cells, with predominantly a mono-unsaturated 
composition. There were specific decreases to diacyl polyunsaturated PC species in CF (mol% PC16:0/ 
18:2=5.16 + I.09 CF vs 7.26 & I.4 control vs 8.89 f 4.23 bronchiectasis; mol % PC16:0/20:4=2.23 * 0.71 CF vs 
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3.4 I-t 1.38 control vs 3.58 + 1.23 bronchiectasis; mole % PC16:0/22:6=0.51 * 0.44 CF vs 1.07 + 0.56 control vs 
0.91 f 0.87 bronchiectasis, PcO.05 for all CF values). There were no decreases to comparable polyunsaturated 
alkylacyl (ether-linked) PC species in CF neutrophils. PMA caused a specific decrease (33%) to PC16:0/20:4 in 
control but not CF neutrophils. This impaired signalling response is consistent with a diminished neutrophil 
respiratory oxidative burst response to S. aureu~ in CF, with a lower proportion of activated cells (6.7% CF vs 
14.1% control) and a lower increase in median fluorescence intensity (5.5-fold CF vs 8.7-fold control). 
Generation and characterization of conditionally immortal murine CF tracheal epithelial 
cell lines 
E. J. THOMAS, S. I? HARDY AND M. I. LETHEM 
Department of Pharmacy, University of Brighton, Brighton, U.K. 
Studies of CF in the mouse are limited by the availability and size of the tissues, a problem which could be 
alleviated by appropriate cell lies. The present study used mice which contain both a knockout for CFTR and the 
gene for a temperature sensitive T-antigen to generate conditionally immortal cell lines in which proliferation can 
be regulated. Heterozygous CF mice ( & ) (UNC) were crossed with H-2kb-tsA58 mice (Immortomouse) 
containing the temperature sensitive tsA58 mutant of SV40 Large T-antigen. Mice which were heterozygous for 
both CF and tsA58 were interbred and subsequent generations used to generate two tracheal epithelial cell lines; 
MTE18 (homozygous CFTR knockout, - / - ) and MTE7b (hetorozygous CFTR, +/ - ). When cultured at 
33°C (the permissive temperature for tsA58 activity), both cell lines display a stable rate of proliferation and have 
reached a high number of population doublings: 176 (MTEl S), 128 (MTE7b). The tsA58 and epithelial nature of 
the cell lines has been confirmed by immunohistochemical staining for T-antigen and cytokeratins. Culture of 
both cell lines at the non-permissive temperature (39.5”C) resulted in a significant (P<O.OOOl) reduction in colony 
forming efficiency: 85.9% (MTE18), 63.5% (MTE7b) indicating the conditional nature of both immortalizations. 
For electrophysiological measurements, cells were cultured on collagen-coated matrices, mounted in Ussing 
chambers and examined under short circuit conditions. Each cell line formed polarized monolayers as indicated 
by moderate transepithelial resistances: 187 & 14.5 &m2 (MTE18), 348 & 35.3 &n-r2 (MTE7b) and basal short 
circuit currents (Is,): 4.2 ?Z 0.3 ,uAcm - 2 (MTEI S), 2.6 f 0.2 PAcm - 2 (MTE7b). Both cell lines failed to respond 
to a range of CAMP mediated stimuli (dibutyryl CAMP, IBMX, forskolin) but responded to ionomycin (10 - 6 M) 
with similar increases in I,,: 5.6 f 2.6 PAcm ~ 2 (MTE18) and 3.7 f 2.4,uAcmm2 (MTE7b). ATP (10 -’ M) 
induced an increase in the Is, of both cell lines: 26.5 * 3.7 PAcm - 2 (MTE18), 16.3 & 1.4 PAcm - 2 (MTE7b), the 
extent and duration of this increase being significantly (PcO.05) greater in the CF - I - cell line. 
Neutrophil migration across human pulmonary endothelial monolayers 
A. J. MACKAREL”, D. C. COTTELLt, M. X. FITZGERALD* AND C. M. O’CONNOR” 
Departments of “Medicine and ?-Electron Microscopy Unit, University College Dublin, BelJield, Dublin 4, 
Ireland 
Animal studies suggest that neutrophil-endothelial interactions mediating pulmonary inflammation differ from 
those involved during systemic inflammation (Doerschuk et al. J Immunol 1990; 11: 2327-2333). The aim of this 
study was to establish an in vitro model to examine these interactions. Human pulmonary artery endothelial cells 
(HPAEC) were grown on microporous membrane filter inserts, coated with human type IV collagen. After 4 
days, the HPAEC filters were fixed in 2.5% glutaraldehyde, post-fixed in 0.1% osmium tetroxide, dehydrated in 
ethanol and either prepared for examination by scanning electron microscopy (SEM) or by transmission electron 
microscopy (TEM). To examine neutrophil-endothelial interactions, neutrophils (isolated from human venous 
blood) were added to HPAEC cultures and allowed to migrate for 5 min at which point the cultures were 
prepared for TEM as described above. SEM demonstrated that HPAEC formed a continuous layer covering the 
entire filter surface. TEM of transverse sections of these HPAEC cultures revealed the presence of a bilayer of 
endothelial cells, a monolayer with subendothelial basal lamina on each side of the filter. In response to a 
transendothelial gradient of the chemoattractant, n-formylmethionylleucyl-phenylalanine (FMLP), neutrophils 
traversed the HPAEC bilayer system by penetrating the endothelium through the intercellular junctions, moving 
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through the 3,um filter pores to come to lie between the filter and the second basal lamina and endothelium, 
before emerging through the endothelial intercellular junctions to complete transmigration. In viva, the blood-air 
barrier comprises two cell monolayers, the pulmonary endothelial wall of the blood vessel and the attenuated 
pulmonary epithelium lining the air-space, which are separated in many areas by just basal lamina. The HPAEC 
bilayer described here, by providing two distinct cell barriers separated by basal lamina, is therefore a closer 
in vitro representation of the blood-air barrier than the single cell-monolayer models used to data and is 
an improved system for use in in vitro studies of the cellular mechanisms involved in leukocyte transmigration to 
the lung. 
This work was funded by the Health Research Board, Ireland. 
Characterization of soot: surface and internal properties 
K. A. B~RuB~“, T. I? JoNEst, B. J. WILLIAMSON+, F. D. POOLEY§ AND R. J. RICHARDS” 
*School of Molecular and Medical Biosciences, ?-Earth Sciences, §Engineering, University of Wales, Cardtf and 
$Natural History Museum, London, U.K. 
Increasing concern is being expressed about the possible health effects of particulate emissions from internal 
combustion engines. The authors’ overall objective is to determine whether PM,,, particulate matter with an 
aerodynamic diameter less than 10 ,um have adverse effects on the lung, and if so, to identify the physico-chemical 
properties that may be important in this regard. Carbon black (CB) and diesel exhaust particulates (DEP) were 
used in this study because in the U.K. DEP forms between 20 and 80% of the mass of PM,, collected on filters 
located in urban sites, and CB exhibits similar aggregation properties and yet has a less complicated chemistry. 
Standardized protocols have been developed for the characterization of particles using the following methods: 
transmission electron microscopy (TEM); field emission scanning electron microscopy (FESEM); X-ray 
diffraction (XRD) and TEM-electron probe X-ray microanalysis (TEM-EPXMA). TEM was used to monitor 
changes in morphological parameters such as size, shape and degree of particle aggregation. TEM data for DEP 
and CB revealed three basic categories of particle morphology: (1) individual particles (spherulites); (2) 
aggregates (chain-like or grape-bunch); and (3) agglomerates (spherules). FESEM, used to study the micromor- 
phology of particles, showed that the aggregates and agglomerates do not exist as solid masses but as loose 
arrangements of spherulites. Calculations of average crystallite size from XRD patterns indicated that CB 
(1.4-1.7 nm) is comparable to DEP (141.6 nm) and is therefore a reliable surrogate control. EPXMA was used 
to determine the elemental composition of particle surfaces, i.e. outermost atomic layers, and internal 
(cross-sections of resin, embedded material) layers. CB has a much simpler surface profile (C, 0, traces of CI, S, 
Si) when compared to diesel (C, 0, Mg, Al, Si, P, Cl, K, Ca, Mn, Fe, Zn), which contains additional metals. The 
internal profile of CB is also more complicated than its surface and is very similar to the surface profile of DEP. 
Internal elemental profiles for DEP revealed the presence of heavy metals (Ti, Cr, Mn, Co, Cu, Pb) not readily 
found on their surfaces. These techniques will now be used to determine where the particles are located and if they 
are durable in lung tissue and fluids. 
Clinical significance of unusual Gram-negative non-fermentative organisms in the 
CF lung 
C. GILLOVV”, P. G. MURPHY*, J. E. MOORE”, A. SHAW* AND S. ELBORNt 
*Molecular Epidemiology Research Unit, N. Ireland, Public Health Laboratory, Belfast City Hospital and 
j-N. Ireland Regional Cystic Fibrosis Centre, Department of Respiratory Medicine, Belfast City Hospital, 
Belfast, N. Ireland, U.K. 
Although Pseudomonas aeruginosa and Burkholderia cepacia are well recognized in initiating infection and 
inflammation in the CF lung, there are a number of closely related Gram-negative organisms belonging to the 
Stenotrophomonas, Chromobacterium, Aeromonas, Alcaligenes genera, as well as the CDC group IV C2 
organisms, whose pathogenicity is not as clearly understood. The aim of the study was to assess the role of these 
relatively antibiotic resistant species, in exacerbation of pulmonary disease in CF. Fifteen isolates were collected 
in the sputum of adult CF patients over a 6-month period (1 January 1996-3 1 July 1996) during a period of active 
clinical infection and were characterized using the AP120NE system. Of these, Alcaligenes xylosoxidans (n=2), 
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Stenotrophomonas maltophilia (n = 2), Aceintobacter lwoji (n = l), Aeronomas salmonicida (n = 2), Aeromonas spp. 
(n=l), Chromobacterium violaceum (n=l), Burkholderia cepacia (n= l), Pseudomonas stutzeri (n= l), Pseudomonas 
jluorescens (n= I), Pseudomonas putida (n= l), Burkholderia pickettii (n=l), CDC group IV C-2 (n= 1) were 
identified. Antibiotic susceptibilities were performed by the Modified Stokes technique and minimum inhibitory 
concentrations (MICs) were determined by the E-test method. In addition, clinico-pathological significance of the 
presence of these organisms in the lung was assessed quantitatively by FEV,, FVC, FEF, PEFR, WBC and CRP. 
Meropenem was the most active of the four iv. antibiotics evaluated (tazobactam, ceftazidime, imipenem and 
meropenem) by E-test in this population. MIC,, values were ~32, ~24, ~32 and <6yg ml- ‘, respectively. This 
study demonstrated that an extended bacteriological protocol will uncover many other related species some of 
which may well contribute to lung damage either per se or possibly as co-pathogens in CF. The assessment of a 
culture as either a pathogen or a colonizing non-pathogen is often difficult. The evidence presented here suggests 
the potential role of these 10 different bacterial species which appear closely related to the classical pathogens, in 
making a significant contribution to lung infection in the CF population. The existence of these related species, 
particularly those with broad antibiotic resistance should not be ignored. Supported by the Royal College of 
Pathologists. 
The IgA secretory component inhibits IL-S function 
B. PERKS AND J. K. SHUTE 
Immunopharmacology Group, Southampton General Hospital, Southampton, U.K. 
It is well established that concentrations of IL-S in the airways of patients with cystic fibrosis (CF) are 
significantly higher than those in normal individuals. The authors previously reported that 97% of this IL-8 is in 
the form of complexes with macromolecules, including IgA, IgG and a,-macroglobulin. This study investigated 
the interaction of IL-8 with another member of the immunoglobulin superfamily, secretory component (SC), the 
extracellular ligand-binding domain of the polymeric IgA receptor. 
CF sputa were collected from paediatric outpatient clinics at Southampton General Hospital. Normal sputa 
were induced by inhalation of nebulized 4.5 M NaCl. Total IL-8 was measured by ELISA (Pelikine, Euro- 
genetics). IgA and SC were measured by specific in-house ELISA. Neutrophils (PMN) were purified from normal 
blood by dextran sedimentation followed by isolation on lymphoprep. Chemotactic responses were assayed in 
micro-Boyden chambers using 5 pm pore-size polycarbonate filters. Migrated cells adherent to the underside of 
the filter were fixed and stained for counting. 
The concentration of SC was significantly (P=O.O04) higher in sputa from CF patients [218.1 (86.2-487.5) nM] 
compared with that from normal subjects [2.3 (O-5.6) nM]. The concentration of total IL-8 in CF sputa [18.7 
(11.7-29.2) nM] was significantly (P<O.OOOl) higher compared with normal sputa [O.l (O-0.2) nM]. Purified SC in 
the concentration range 0.1-6.3 nM dose dependently inhibited the PMN chemotactic response to an optimal 
concentration of hrIL-8 (IO- * M). Chemotaxis was completely inhibited by 6.3 f 0.1 nM SC, and the IC,, for 
the inhibition was 0.46 f 0.05 nM SC. 
These results suggest that SC may inhibit the inflammatory effects of IL-8 in normal airways and that the 
SC/IL-8 balance may be disturbed in the PMN mediated inflammatory response in CF. 
Inflammation in cystic fibrosis (CF): the heparin heparinase balance in CF compared to 
normal airways 
L. S. P. RAMDIN AND J. K. SHUTE 
University Medicine, Southampton General Hospital, Southampton, U.K. 
The anti-inflammatory effects of heparin relevant to the regulation of both allergic and non-allergic inflammation 
are well described. Relevant to CF is the authors’ previous observation that heparin inhibits IL-8 binding and 
function. Endoglycosidases or heparinases mediate the catabolism of heparin and therefore represent an 
important determinant of such effects. 
To detect and quantify heparinase activity, the authors have developed a novel, non-radioactive technique. 
Their method employs substrate gel zymography, incorporating heparin into polyacrylamide gels. Detection of 
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heparin degradation is by substrate staining with azure A and silver stain followed by scanning densitometry. 
Heparinase activity was measured in the sputum of patients with CF and sputum induced by inhalation of 
hypertonic saline in normal subjects. Heparin was measured in sputum by inhibition of factor Xa activity 
following its displacement with dextran sulphate. 
Significantly higher levels of heparinase activity were detected in the sputum of CF (156 * 75 units) compared 
to normal subjects (11.89 * 8.23). Conversely, heparin was undetectable in CF sputum and was significantly 
lower than in normal sputum (1.857 f 0.09,~g ml- ‘). Further, there was a significant negative correlation 
(r= - 0.84, WO.01) b e ween heparin concentrations and heparinase activity. t 
These findings indicate that the normal heparin/heparinase balance is perturbed in inflammation of the 
airways, resulting in a net increase in heparinase activity and a consequent decrease in the anti-inflammatory 
potential of heparin. Further, this suggests that IL-8 bioactivity may be inhibited by heparin in normal lung tissue 
but not in the inflamed CF lung. 
The activity of plasma esterases in patients with cystic fibrosis 
L. S. NIXON, K. ABOU-HATAB”, M. S. O’MAHONY*, K. WOODHOUSE” AND D. J. SHALE 
Section of Respiratory Medicine and *Department of Geriatric Medicine, UWCM, Llandough Hospital, Penarth, 
CardifJ; UK. 
Cholinesterases exhibit additional activities apart from their well-known action in hydrolysing choline esters. 
Low levels of butyrylcholinesterase (ButChe) has been reported to be a marker of poor nutritional status, and has 
also been related to inflammatory activity. Eighteen patients with cystic fibrosis were studied at the start of a 
respiratory exacerbation, and again after 2 weeks antibiotic treatment. Eighteen age- and sex-matched controls 
were also studied. The activities of benzoylcholinesterase (BnzChe) and ButChe were determined in plasma 
samples spectrophotometrically. There was a significant rise for both enzymes with antibiotic treatment (PcO.04). 
Values for both enzymes were lower in patients than controls. This was significant (PcO.01) at the start of an 
exacerbation. In these patients, the markers of inflammation C-reactive Protein (CRP) and neutrophil elastase 
anti-proteinase complex (NEAPC) showed a significant fall. 
Start of exacerbation 2 weeks treatment Controls 
BnzChe (U ml - ‘) 918.1 * 70.7 1017.4 i. 64.2 1245.2 & 80.3 
ButChe (U ml - ‘) 4.89 + 0.33 5.76 zt 0.37 6.42 zt 0.42 
CRP @gml-1 32.76 i 9.46 6.67 f 2.02 1.11 & 0.34 
NEAPC (ng ml ~ ‘) 59.95 i 10.2 43.7 zt 5.96 28.35 xt 3.75 
(Arithmetic mean % SEM) 
At the start of an exacerbation, both enzymes were lower in patients with reduced FVC (rz0.90, P=O.O02 for 
ButChe and rzO.787, PzO.017 for BnzChe). This tended to be those patients with poor nutritional status. It is 
concluded that acute exacerbations of cystic fibrosis are associated with lower activity of plasma esterases which 
could result in alterations in the body’s ability to metabolise drugs during acute infection. 
Downregulation of neutrophils from patients with cystic fibrosis: a receptor 
mechanism? 
L. S. NIXON, A. IONESCU AND D. J. SHALE 
Section of Respiratory Medicine, UWCM, Llundough Hospital, Penarth, CurdifJ; U.K. 
Neutrophils are important in the host response and clearance of infection. Previous research in patients with 
cystic fibrosis (CF) (Israel J Med Sci 1996; 32: S188) has shown downregulation of the neutrophil response to 
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fMLP for superoxide generation and elastase release at the start of an exacerbation, returning to normal after 
antibiotic treatment. To determine the possible receptor-based nature of this effect, the authors studied six 
patients with CF. The superoxide generation in response to Phorbol-12-myristate-13-acetate (PMA) was 
compared to fMLP. PMA acts intracellularly on protein kinases to produce superoxide, whereas fMLP acts via 
a cell surface receptor. Superoxide generation was measured by the reduction of cytochrome C (nmol cytochrome 
C reduced/lo6 neutrophils/20 min). Superoxide generation was significantly reduced in patients in exacerbation 
compared to controls for fMLP in the absence and presence of cytochalasin B (CB). There was no significant 
difference between the response to PMA compared to controls. 
fMLP fMLP 






+CB 1O-7 M 
CF start 4.07 12.7 21.0 29.1 28.6 
Control 7.55 20.1 25.8 29.9 29.4 
Significance 0.027 0.011 0.017 ns ns 
There was no significant difference between superoxide generation by neutrophils from patients at the end of 
an exacerbation and controls. These results suggest that the reduced responsiveness of neutrophils from patients 
with CF at the start of an exacerbation is linked to reduced receptor number or function, rather than a reduced 
ability of these cells to produce superoxide. 
L. S. Nixon was supported by CF Trust U.K. 
Soluble L-selectin in cystic fibrosis (CF) 
L. S. NIXON AND D. J. SHALE 
Section of Respiratory Medicine, UWCM, Llandough Hospital, Penarth, CardiSJ; U.K. 
L-selectin shedding from the surface membrane of neutrophils is considered to indicate activation. The authors 
studied 12 adult patients with CF at the start of a pulmonary exacerbation and after 2 weeks of specific 
anti-pseudomonal antibiotic treatment. Patients were compared with 12 age- and sex-matched healthy non-CF 
subjects. Soluble (s) L-selectin was measured in plasma by ELISA (R & D systems). CRP, NEAPC, IL-6 and 
TNF-a were measured as previously described (Pediatr Pulmonol 1996; 13 (Suppl. 429). sL-selectin increased 
significantly following treatment (P=O.O006). Despite this increase sL-selectin levels were not significantly 
different from control values at either time points. sL-selectin/neutrophil was lower (PzO.03) at the beginning of 
an exacerbation and higher (PzO.02) after treatment. The level of sL-selectin was inversely related to the absolute 
neutrophil count (r= - 0.057; PzO.07). The directional change of sL-selectin was also different to that of other 
inflammatory markers. 
Start of exacerbation After treatment Control 
sL selectin (ng ml - ‘) 
Neuts (lo6 ml- ‘) 
sL selectin/106 neuts 
NEAPC (ng ml - ‘) 
CRP kg ml - ‘) 
fMLP stim - NE release 
(ng 10W6 neuts) 
SO4 (692-935) 958 (81 l-1081) 8 12 (703-938) 
8.92 3~ 0.99 3.59 It 0.37 5.54 f 0.59 
104ztfr.3 283 YII 34 180 zt 31 
29.3 (24-35) 22.6 (1 S-28) 17.3 (13-22) 
21.3 (9-53) 2.75 (14-5.6) 0.33 (0.2-0.7) 
522 I!= 66 616& 110 670 f 132 
(Arithmetic mean & SEM: Geometric mean (95% CI) 
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This apparent downregulation of sL-selectin shedding in the circulation at the time of an exacerbation is in 
keeping with reported downregulation of superoxide formation and elastase release in response to fMLP by 
neutrophils at the time of an exacerbation, with correction following antibiotic treatment (Israel J Med Sci 1996; 
32 (Suppl. SISS). The mechanism of downregulation of neutrophil activation is unknown and its role unclear, 
although it may be a means of regulating neutrophil activity at a site of infection/inflammation. 
L. S. Nixon was supported by Cystic Fibrosis Trust U.K. 
